{"569bef7eba03a7eca3bbc604e77c27fd7f48c2e4": [], "5fcad8178f6a40eeb46d4ecb0d590c4ebf4622c0": [["INTRODUCTIONPrimary immunodeficiencies (PIDs) are inherited conditions characterized by recurrent infections, inflammatory disorders, and autoimmunity.", [["INTRODUCTIONPrimary immunodeficiencies", "DISEASE", 0, 38], ["PIDs", "DISEASE", 40, 44], ["infections", "DISEASE", 98, 108], ["inflammatory disorders", "DISEASE", 110, 132], ["autoimmunity", "DISEASE", 138, 150], ["INTRODUCTIONPrimary immunodeficiencies (PIDs", "PROBLEM", 0, 44], ["inherited conditions", "PROBLEM", 50, 70], ["recurrent infections", "PROBLEM", 88, 108], ["inflammatory disorders", "PROBLEM", 110, 132], ["autoimmunity", "PROBLEM", 138, 150], ["recurrent", "OBSERVATION_MODIFIER", 88, 97], ["infections", "OBSERVATION", 98, 108], ["inflammatory", "OBSERVATION_MODIFIER", 110, 122]]], ["Severe combined immunodeficiency (SCID), the most severe form of PID, is usually fatal within the first year of life unless corrected [1] .", [["Severe combined immunodeficiency", "DISEASE", 0, 32], ["SCID", "DISEASE", 34, 38], ["PID", "DISEASE", 65, 68], ["Severe combined immunodeficiency (SCID)", "PROBLEM", 0, 39], ["PID", "PROBLEM", 65, 68], ["immunodeficiency", "OBSERVATION", 16, 32], ["most severe", "OBSERVATION_MODIFIER", 45, 56]]], ["Other T cell and innate immune defects have excessive morbidity and mortality through childhood and early adulthood.", [["T cell", "ANATOMY", 6, 12], ["T cell", "CELL", 6, 12], ["Other T cell", "PROBLEM", 0, 12], ["innate immune defects", "PROBLEM", 17, 38], ["excessive morbidity", "PROBLEM", 44, 63], ["cell", "OBSERVATION", 8, 12], ["immune defects", "OBSERVATION", 24, 38], ["excessive", "OBSERVATION_MODIFIER", 44, 53], ["morbidity", "OBSERVATION", 54, 63]]], ["Hematopoietic stem cell transplantation (HSCT) is curative for many patients with a 10-year survival of 84% in HLA-matched sibling HSCT for SCID [2, 3] .", [["Hematopoietic stem cell", "ANATOMY", 0, 23], ["SCID", "DISEASE", 140, 144], ["Hematopoietic stem cell", "CELL", 0, 23], ["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76], ["Hematopoietic stem cell transplantation", "TREATMENT", 0, 39], ["SCID", "PROBLEM", 140, 144], ["stem cell transplantation", "OBSERVATION", 14, 39]]], ["Ten-year survival for non-SCID PID is 71% for HLA-matched sibling HSCT, with survival rates improving over time [2, 3] .INTRODUCTIONUmbilical cord blood offers an alternative source of stem cells for transplantation (cord blood transplantation, CBT) when a matched sibling donor is unavailable.", [["cord blood", "ANATOMY", 142, 152], ["stem cells", "ANATOMY", 185, 195], ["cord blood", "ANATOMY", 217, 227], ["PID", "DISEASE", 31, 34], ["cord", "ORGANISM_SUBSTANCE", 142, 146], ["blood", "ORGANISM_SUBSTANCE", 147, 152], ["stem cells", "CELL", 185, 195], ["cord blood", "MULTI-TISSUE_STRUCTURE", 217, 227], ["stem cells", "CELL_TYPE", 185, 195], ["HLA", "PROBLEM", 46, 49], ["survival rates", "TEST", 77, 91], ["stem cells", "TREATMENT", 185, 195], ["transplantation (cord blood transplantation", "TREATMENT", 200, 243], ["cord", "ANATOMY", 142, 146], ["stem cells", "OBSERVATION", 185, 195]]], ["Advantages and disadvantages of CBT over bone marrow transplantation (BMT) and peripheral blood stem cells (PBSC) are reviewed in detail elsewhere [4, 5] .", [["bone marrow", "ANATOMY", 41, 52], ["peripheral blood stem cells", "ANATOMY", 79, 106], ["PBSC", "ANATOMY", 108, 112], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 41, 52], ["peripheral blood stem cells", "CELL", 79, 106], ["PBSC", "CELL", 108, 112], ["peripheral blood stem cells", "CELL_TYPE", 79, 106], ["PBSC", "CELL_TYPE", 108, 112], ["CBT over bone marrow transplantation", "TREATMENT", 32, 68], ["peripheral blood stem cells", "TEST", 79, 106], ["bone marrow", "ANATOMY", 41, 52], ["peripheral", "ANATOMY_MODIFIER", 79, 89], ["blood", "ANATOMY", 90, 95], ["stem cells", "OBSERVATION", 96, 106]]], ["Advantages include (1) easy access to the cord blood unit and, therefore, earlier transplantation;INTRODUCTION(2) absence of risk to donor; (3) lower risk of latent viral transmission and graft-versus-host disease (GvHD); and (4) higher chance of matching rare HLA haplotypes.", [["cord blood", "ANATOMY", 42, 52], ["graft", "ANATOMY", 188, 193], ["graft-versus-host disease", "DISEASE", 188, 213], ["GvHD", "DISEASE", 215, 219], ["cord blood", "MULTI-TISSUE_STRUCTURE", 42, 52], ["earlier transplantation", "TREATMENT", 74, 97], ["latent viral transmission", "PROBLEM", 158, 183], ["graft-versus-host disease", "PROBLEM", 188, 213], ["GvHD", "PROBLEM", 215, 219], ["matching rare HLA haplotypes", "PROBLEM", 247, 275], ["cord", "ANATOMY", 42, 46], ["latent", "OBSERVATION_MODIFIER", 158, 164], ["viral", "OBSERVATION", 165, 170], ["graft", "OBSERVATION", 188, 193], ["host disease", "OBSERVATION", 201, 213]]], ["However, the stem cell dose is often low and unrelated donors are not available for boost HSCT.", [["stem cell", "ANATOMY", 13, 22], ["stem cell", "CELL", 13, 22], ["donors", "ORGANISM", 55, 61], ["the stem cell dose", "TREATMENT", 9, 27], ["boost HSCT", "TREATMENT", 84, 94], ["stem cell", "OBSERVATION", 13, 22]]], ["Cord blood units are virologically na\u00efve and often show slower engraftment due to a lower CD34 \u00fe dose compared to BMT and PBSCs.", [["Cord blood", "ANATOMY", 0, 10], ["PBSCs", "ANATOMY", 122, 127], ["Cord", "ORGANISM_SUBSTANCE", 0, 4], ["blood", "ORGANISM_SUBSTANCE", 5, 10], ["CD34", "GENE_OR_GENE_PRODUCT", 90, 94], ["PBSCs", "CANCER", 122, 127], ["CD34", "PROTEIN", 90, 94], ["PBSCs", "CELL_TYPE", 122, 127], ["Cord blood units", "TEST", 0, 16], ["virologically na\u00efve", "TEST", 21, 40], ["slower engraftment", "PROBLEM", 56, 74], ["a lower CD34 \u00fe dose", "TREATMENT", 82, 101], ["BMT and PBSCs", "TREATMENT", 114, 127], ["slower engraftment", "OBSERVATION", 56, 74]]], ["Both of these factors increase the risks from pre-existing infections in CBT for PID patients.INTRODUCTIONEvidence for the effectiveness of CBT in PID comes from a few single center and multicenter studies [6] [7] [8] [9] [10] .", [["infections", "DISEASE", 59, 69], ["PID", "DISEASE", 81, 84], ["PID", "DISEASE", 147, 150], ["patients", "ORGANISM", 85, 93], ["[6] [7] [8] [9] [10]", "SIMPLE_CHEMICAL", 206, 226], ["patients", "SPECIES", 85, 93], ["pre-existing infections", "PROBLEM", 46, 69], ["PID patients", "TREATMENT", 81, 93], ["CBT in PID", "TREATMENT", 140, 150], ["multicenter studies", "TEST", 186, 205], ["infections", "OBSERVATION", 59, 69]]], ["A recent study demonstrated a lower rate of grades II to IV GvHD and improved survival in unrelated CBT when the authors compared their results with similar studies of BMT for PID and that mortality was associated with pre-existing infection, no conditioning, !2 HLA mismatch and underlying disease [10] .", [["GvHD", "DISEASE", 60, 64], ["PID", "DISEASE", 176, 179], ["infection", "DISEASE", 232, 241], ["A recent study", "TEST", 0, 14], ["IV GvHD", "TREATMENT", 57, 64], ["BMT", "TREATMENT", 168, 171], ["PID", "PROBLEM", 176, 179], ["pre-existing infection", "PROBLEM", 219, 241], ["HLA mismatch", "PROBLEM", 263, 275], ["underlying disease", "PROBLEM", 280, 298], ["GvHD", "OBSERVATION", 60, 64], ["infection", "OBSERVATION", 232, 241], ["no", "UNCERTAINTY", 243, 245]]], ["However, this study does not provide data on lymphocyte reconstitution or long-term graft function.", [["lymphocyte", "ANATOMY", 45, 55], ["graft", "ANATOMY", 84, 89], ["lymphocyte", "CELL", 45, 55], ["graft", "TISSUE", 84, 89], ["this study", "TEST", 9, 19], ["lymphocyte reconstitution", "TREATMENT", 45, 70], ["long-term graft function", "TREATMENT", 74, 98], ["long-term", "OBSERVATION_MODIFIER", 74, 83], ["graft", "OBSERVATION", 84, 89]]], ["Other studies with limited data on lymphocyte reconstitution show that absolute lymphocyte counts increase from 2 months with a proportional increase in CD4 \u00fe and CD8 \u00fe T cells from 3 months post CBT and that age-related normal values for CD19 \u00fe , CD3 \u00fe , and CD4 \u00fe are reached by 24 months in all patients studied [7, 11] .", [["lymphocyte", "ANATOMY", 35, 45], ["lymphocyte", "ANATOMY", 80, 90], ["CD4 \u00fe", "ANATOMY", 153, 158], ["CD8 \u00fe T cells", "ANATOMY", 163, 176], ["lymphocyte", "CELL", 35, 45], ["lymphocyte", "CELL", 80, 90], ["CD4 \u00fe", "GENE_OR_GENE_PRODUCT", 153, 158], ["CD8", "GENE_OR_GENE_PRODUCT", 163, 166], ["CD19", "GENE_OR_GENE_PRODUCT", 239, 243], ["CD3", "GENE_OR_GENE_PRODUCT", 248, 251], ["CD4", "GENE_OR_GENE_PRODUCT", 260, 263], ["patients", "ORGANISM", 298, 306], ["CD4", "PROTEIN", 153, 156], ["CD8 \u00fe T cells", "CELL_TYPE", 163, 176], ["CD19", "PROTEIN", 239, 243], ["CD3", "PROTEIN", 248, 251], ["CD4", "PROTEIN", 260, 263], ["patients", "SPECIES", 298, 306], ["Other studies", "TEST", 0, 13], ["lymphocyte reconstitution", "TREATMENT", 35, 60], ["absolute lymphocyte counts", "TEST", 71, 97], ["a proportional increase", "PROBLEM", 126, 149], ["CD4", "TEST", 153, 156], ["CD8 \u00fe T cells", "PROBLEM", 163, 176], ["CBT", "TEST", 196, 199], ["CD19", "TEST", 239, 243], ["CD3", "TEST", 248, 251], ["CD4", "TEST", 260, 263], ["absolute lymphocyte counts", "OBSERVATION", 71, 97], ["increase", "OBSERVATION_MODIFIER", 141, 149]]], ["All surviving patients in 1 series were independent of intravenous immunoglobulin and responded to T cell stimulation, tetanus, and hepatitis B vaccination [7] .INTRODUCTIONSerotherapy in the form alemtuzumab (T and B cell depleting anti-CD52 humanized monoclonal antibody) is added to conditioning regimens to reduce the incidence of GvHD [12] [13] [14] [15] [16] .", [["intravenous", "ANATOMY", 55, 66], ["T cell", "ANATOMY", 99, 105], ["B cell", "ANATOMY", 216, 222], ["tetanus", "DISEASE", 119, 126], ["hepatitis B", "DISEASE", 132, 143], ["alemtuzumab", "CHEMICAL", 197, 208], ["GvHD", "DISEASE", 335, 339], ["patients", "ORGANISM", 14, 22], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 55, 66], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 67, 81], ["T cell", "CELL", 99, 105], ["hepatitis B", "ORGANISM", 132, 143], ["alemtuzumab", "SIMPLE_CHEMICAL", 197, 208], ["T", "CELL", 210, 211], ["B cell", "CELL", 216, 222], ["[12] [13] [14] [15] [16]", "SIMPLE_CHEMICAL", 340, 364], ["intravenous immunoglobulin", "PROTEIN", 55, 81], ["T and B cell depleting anti-CD52 humanized monoclonal antibody", "PROTEIN", 210, 272], ["patients", "SPECIES", 14, 22], ["intravenous immunoglobulin", "TREATMENT", 55, 81], ["T cell stimulation", "TREATMENT", 99, 117], ["tetanus", "TREATMENT", 119, 126], ["hepatitis B vaccination", "TREATMENT", 132, 155], [".INTRODUCTIONSerotherapy", "TREATMENT", 160, 184], ["alemtuzumab (T and B cell depleting anti-CD52 humanized monoclonal antibody)", "TREATMENT", 197, 273], ["conditioning regimens", "TREATMENT", 286, 307], ["GvHD", "PROBLEM", 335, 339]]], ["Immune reconstitution is delayed by alemtuzumab in patients with malignant and nonmalignant hematological conditions [13, 16, 17] with some studies suggesting slower immune reconstitution with higher doses used [12, 18] .", [["nonmalignant hematological", "ANATOMY", 79, 105], ["alemtuzumab", "CHEMICAL", 36, 47], ["alemtuzumab", "SIMPLE_CHEMICAL", 36, 47], ["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59], ["Immune reconstitution", "TREATMENT", 0, 21], ["alemtuzumab", "TREATMENT", 36, 47], ["malignant and nonmalignant hematological conditions", "PROBLEM", 65, 116], ["some studies", "TEST", 135, 147], ["slower immune reconstitution", "PROBLEM", 159, 187], ["malignant", "OBSERVATION_MODIFIER", 65, 74], ["nonmalignant", "OBSERVATION_MODIFIER", 79, 91], ["suggesting", "UNCERTAINTY", 148, 158], ["slower", "OBSERVATION_MODIFIER", 159, 165], ["immune reconstitution", "OBSERVATION", 166, 187]]], ["This slower immune reconstitution is, in turn, associated with an increased incidence of viral reactivation, notably cytomegalovirus [17, [20] [21] [22] , adenovirus [14, 23, 24] and respiratory viruses [25] .", [["respiratory viruses", "DISEASE", 183, 202], ["cytomegalovirus", "ORGANISM", 117, 132], ["adenovirus", "ORGANISM", 155, 165], ["This slower immune reconstitution", "PROBLEM", 0, 33], ["viral reactivation", "PROBLEM", 89, 107], ["cytomegalovirus", "TEST", 117, 132], ["adenovirus", "TEST", 155, 165], ["respiratory viruses", "TEST", 183, 202], ["immune reconstitution", "OBSERVATION", 12, 33], ["increased", "OBSERVATION_MODIFIER", 66, 75], ["viral reactivation", "OBSERVATION", 89, 107], ["cytomegalovirus", "OBSERVATION", 117, 132], ["respiratory", "ANATOMY", 183, 194], ["viruses", "OBSERVATION", 195, 202]]], ["This is particularly pertinent when considering CBT for PID because many patients have active or latent viral infections at the time of HSCT and CBT is considered to have slower immune reconstitution and be virologically na\u00efve [4, 5] .", [["PID", "DISEASE", 56, 59], ["viral infections", "DISEASE", 104, 120], ["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81], ["CBT", "TEST", 48, 51], ["PID", "PROBLEM", 56, 59], ["latent viral infections", "PROBLEM", 97, 120], ["HSCT", "TEST", 136, 140], ["CBT", "TEST", 145, 148], ["slower immune reconstitution", "PROBLEM", 171, 199], ["active", "OBSERVATION_MODIFIER", 87, 93], ["latent", "OBSERVATION_MODIFIER", 97, 103], ["viral", "OBSERVATION_MODIFIER", 104, 109], ["infections", "OBSERVATION", 110, 120]]], ["The role of serotherapy in CBT for PID has not been explored to date.", [["PID", "DISEASE", 35, 38], ["serotherapy in CBT", "TREATMENT", 12, 30], ["PID", "PROBLEM", 35, 38]]], ["We report the results of a retrospective study of the effects of 2 alemtuzumab-based serotherapy dose regimens on lymphocyte reconstitution, GvHD, viral infection, and mortality in PID patients who underwent CBT at an international center.Patients and Exclusion CriteriaThirty-four consecutive patients who underwent CBT for PID between May 1999 and December 2010 at the Children's BMT Unit, Newcastle upon Tyne Hospitals NHS Foundation Trust, United Kingdom were identified from the unit's database.", [["lymphocyte", "ANATOMY", 114, 124], ["alemtuzumab", "CHEMICAL", 67, 78], ["GvHD", "DISEASE", 141, 145], ["viral infection", "DISEASE", 147, 162], ["PID", "DISEASE", 181, 184], ["PID", "DISEASE", 325, 328], ["alemtuzumab", "SIMPLE_CHEMICAL", 67, 78], ["lymphocyte", "CELL", 114, 124], ["patients", "ORGANISM", 185, 193], ["Patients", "ORGANISM", 239, 247], ["patients", "ORGANISM", 294, 302], ["patients", "SPECIES", 185, 193], ["Patients", "SPECIES", 239, 247], ["patients", "SPECIES", 294, 302], ["Children", "SPECIES", 371, 379], ["a retrospective study", "TEST", 25, 46], ["2 alemtuzumab", "TREATMENT", 65, 78], ["based serotherapy dose regimens", "TREATMENT", 79, 110], ["lymphocyte reconstitution", "TREATMENT", 114, 139], ["GvHD", "PROBLEM", 141, 145], ["viral infection", "PROBLEM", 147, 162], ["CBT", "TEST", 208, 211], ["CBT", "TEST", 317, 320], ["PID", "PROBLEM", 325, 328], ["lymphocyte reconstitution", "OBSERVATION", 114, 139], ["viral infection", "OBSERVATION", 147, 162]]], ["A retrospective study of these patients was performed, of which 14 have been previously reported [6] .", [["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["A retrospective study", "TEST", 0, 21]]], ["There was a systematic change in serotherapy policy at the Children's BMT Unit in 2006 to 2007, when the alemtuzumab dose was reduced to determine if it had the same protective effects on GvHD without an increase in viral infection.", [["alemtuzumab", "CHEMICAL", 105, 116], ["GvHD", "DISEASE", 188, 192], ["viral infection", "DISEASE", 216, 231], ["alemtuzumab", "SIMPLE_CHEMICAL", 105, 116], ["Children", "SPECIES", 59, 67], ["a systematic change", "PROBLEM", 10, 29], ["the alemtuzumab dose", "TREATMENT", 101, 121], ["GvHD", "PROBLEM", 188, 192], ["viral infection", "PROBLEM", 216, 231], ["systematic", "OBSERVATION_MODIFIER", 12, 22], ["change", "OBSERVATION_MODIFIER", 23, 29], ["increase", "OBSERVATION_MODIFIER", 204, 212], ["viral infection", "OBSERVATION", 216, 231]]], ["Two patients were excluded from further analysis because they received alemtuzumab before conditioning at 3 and 4 weeks before CBT, and another was excluded because the patient received rabbit antithymocyte globulin (ATG) instead of alemtuzumb.", [["alemtuzumab", "CHEMICAL", 71, 82], ["antithymocyte globulin", "CHEMICAL", 193, 215], ["ATG", "CHEMICAL", 217, 220], ["alemtuzumb", "CHEMICAL", 233, 243], ["patients", "ORGANISM", 4, 12], ["alemtuzumab", "SIMPLE_CHEMICAL", 71, 82], ["patient", "ORGANISM", 169, 176], ["rabbit", "ORGANISM", 186, 192], ["antithymocyte globulin", "SIMPLE_CHEMICAL", 193, 215], ["ATG", "SIMPLE_CHEMICAL", 217, 220], ["alemtuzumb", "SIMPLE_CHEMICAL", 233, 243], ["rabbit antithymocyte globulin", "PROTEIN", 186, 215], ["patients", "SPECIES", 4, 12], ["patient", "SPECIES", 169, 176], ["rabbit", "SPECIES", 186, 192], ["rabbit", "SPECIES", 186, 192], ["further analysis", "TEST", 32, 48], ["alemtuzumab", "TREATMENT", 71, 82], ["CBT", "TEST", 127, 130], ["rabbit antithymocyte globulin", "TREATMENT", 186, 215], ["ATG", "TREATMENT", 217, 220], ["alemtuzumb", "TREATMENT", 233, 243]]], ["Those who received no serotherapy (n \u00bc 11) were also excluded because 6 did not receive chemotherapeutic conditioning and others were selected to this group based on clinical presentation.", [["serotherapy", "TREATMENT", 22, 33], ["chemotherapeutic conditioning", "TREATMENT", 88, 117]]], ["The remaining patients were retrospectively nonrandomly assigned to highdose (alemtuzumab ! .9 mg/kg given in 5 divided doses before day -10 or between day -8 and day -4; n \u00bc 11) or low-dose (alemtuzumab .3 to .6 mg/kg given in 3 divided doses on consecutive days between day -11 and day -6; n \u00bc 9) serotherapy groups for the purpose of analysis.", [["highdose", "CHEMICAL", 68, 76], ["alemtuzumab", "CHEMICAL", 78, 89], ["alemtuzumab", "CHEMICAL", 192, 203], ["highdose", "CHEMICAL", 68, 76], ["patients", "ORGANISM", 14, 22], ["alemtuzumab", "SIMPLE_CHEMICAL", 78, 89], ["alemtuzumab", "SIMPLE_CHEMICAL", 192, 203], ["patients", "SPECIES", 14, 22], ["alemtuzumab", "TREATMENT", 192, 203]]], ["No alemtuzumab pharmacokinetic studies were performed.", [["alemtuzumab", "CHEMICAL", 3, 14], ["alemtuzumab", "SIMPLE_CHEMICAL", 3, 14], ["alemtuzumab pharmacokinetic studies", "TEST", 3, 38], ["alemtuzumab", "OBSERVATION", 3, 14]]], ["Underlying diagnoses by serotheraphy group are shown in Supplementary Table S1 .Umbilical Cord Transplantation ProcedureSearch for a suitable umbilical cord donor unit was initiated if a matched sibling cord was stored or if a matched sibling donor was unavailable.", [["umbilical cord", "ANATOMY", 142, 156], ["cord", "ANATOMY", 203, 207], ["umbilical cord", "MULTI-TISSUE_STRUCTURE", 142, 156], ["cord", "ORGAN", 203, 207], ["Umbilical Cord Transplantation ProcedureSearch", "TREATMENT", 80, 126], ["a suitable umbilical cord donor unit", "TREATMENT", 131, 167], ["S1", "ANATOMY", 76, 78], ["Cord", "ANATOMY", 90, 94], ["Transplantation", "OBSERVATION", 95, 110], ["umbilical cord", "ANATOMY", 142, 156]]], ["HLA matching was based on low-resolution molecular class I and high-resolution molecular class II typing at 10 HLA loci as previously described [6] .", [["HLA loci", "DNA", 111, 119], ["HLA matching", "PROBLEM", 0, 12]]], ["Patients were conditioned according to the European Blood and Bone Marrow Transplant Group (EBMT) guidelines, EBMT Working Party for Inborn Errors, and clinical condition, and they received either myeloablative conditioning (busulphan 16 mg/kg \u00fe cyclophosphamide 200 mg/kg or treosulphan 36 g/m 2 \u00fe cyclophosphamide 200 mg/kg; n \u00bc 9) or reduced-intensity conditioning (treosulphan 36 g/m 2 \u00fe fludarabine 150 mg/m 2 or fludarabine 150 mg/m 2 \u00fe melphalan 140 mg/m 2 ; n \u00bc 11).", [["Blood", "ANATOMY", 52, 57], ["Bone Marrow", "ANATOMY", 62, 73], ["busulphan", "CHEMICAL", 225, 234], ["cyclophosphamide", "CHEMICAL", 246, 262], ["treosulphan", "CHEMICAL", 276, 287], ["cyclophosphamide", "CHEMICAL", 299, 315], ["treosulphan", "CHEMICAL", 369, 380], ["fludarabine", "CHEMICAL", 392, 403], ["fludarabine", "CHEMICAL", 418, 429], ["melphalan", "CHEMICAL", 443, 452], ["cyclophosphamide", "CHEMICAL", 246, 262], ["treosulphan", "CHEMICAL", 276, 287], ["cyclophosphamide", "CHEMICAL", 299, 315], ["treosulphan", "CHEMICAL", 369, 380], ["fludarabine", "CHEMICAL", 392, 403], ["fludarabine", "CHEMICAL", 418, 429], ["melphalan", "CHEMICAL", 443, 452], ["Patients", "ORGANISM", 0, 8], ["Bone Marrow", "MULTI-TISSUE_STRUCTURE", 62, 73], ["cyclophosphamide", "SIMPLE_CHEMICAL", 246, 262], ["cyclophosphamide", "SIMPLE_CHEMICAL", 299, 315], ["fludarabine", "SIMPLE_CHEMICAL", 392, 403], ["fludarabine", "SIMPLE_CHEMICAL", 418, 429], ["melphalan", "SIMPLE_CHEMICAL", 443, 452], ["Patients", "SPECIES", 0, 8], ["Inborn Errors", "PROBLEM", 133, 146], ["myeloablative conditioning", "TREATMENT", 197, 223], ["busulphan", "TREATMENT", 225, 234], ["cyclophosphamide", "TREATMENT", 246, 262], ["treosulphan", "TREATMENT", 276, 287], ["cyclophosphamide", "TREATMENT", 299, 315], ["reduced-intensity conditioning", "TREATMENT", 337, 367], ["treosulphan", "TREATMENT", 369, 380], ["fludarabine", "TREATMENT", 392, 403], ["fludarabine", "TREATMENT", 418, 429], ["melphalan", "TREATMENT", 443, 452], ["Bone Marrow", "ANATOMY", 62, 73]]], ["Patients also received either high-dose or low-dose serotherapy as part of their conditioning regimen allocated as described above.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["low-dose serotherapy", "TREATMENT", 43, 63], ["their conditioning regimen", "TREATMENT", 75, 101]]], ["The cord blood unit was transfused on day 0 with a median nucleated cell count of 1.30 \u00c2 10 8 cells/kg (range, .36 to 3.8) and a median CD34 \u00fe count of 3.70 \u00c2 10 5 cells/kg (range, .67 to 19.0).Supportive Measures and ProphylaxisAll patients were nursed in HEPA-filtered cubicles.", [["cord blood", "ANATOMY", 4, 14], ["nucleated cell", "ANATOMY", 58, 72], ["cells", "ANATOMY", 94, 99], ["cells", "ANATOMY", 164, 169], ["cord blood", "ORGANISM_SUBSTANCE", 4, 14], ["nucleated cell", "CELL", 58, 72], ["CD34", "GENE_OR_GENE_PRODUCT", 136, 140], ["patients", "ORGANISM", 233, 241], ["CD34", "PROTEIN", 136, 140], ["patients", "SPECIES", 233, 241], ["a median nucleated cell count", "TEST", 49, 78], ["a median CD34 \u00fe count", "TEST", 127, 148], ["kg", "TEST", 170, 172], ["Supportive Measures", "TREATMENT", 194, 213], ["Prophylaxis", "TREATMENT", 218, 229], ["cord", "ANATOMY", 4, 8]]], ["Patients received cyclosporine for GvHD prophylaxis, cotrimoxazole for Pneumocystis jiroveci prophylaxis, liposomal amphotericin for antifungal prophylaxis, and aciclovir for antiviral prophylaxis.", [["cyclosporine", "CHEMICAL", 18, 30], ["GvHD", "DISEASE", 35, 39], ["cotrimoxazole", "CHEMICAL", 53, 66], ["Pneumocystis jiroveci", "DISEASE", 71, 92], ["amphotericin", "CHEMICAL", 116, 128], ["aciclovir", "CHEMICAL", 161, 170], ["cyclosporine", "CHEMICAL", 18, 30], ["cotrimoxazole", "CHEMICAL", 53, 66], ["amphotericin", "CHEMICAL", 116, 128], ["aciclovir", "CHEMICAL", 161, 170], ["Patients", "ORGANISM", 0, 8], ["cyclosporine", "SIMPLE_CHEMICAL", 18, 30], ["cotrimoxazole", "SIMPLE_CHEMICAL", 53, 66], ["liposomal amphotericin", "SIMPLE_CHEMICAL", 106, 128], ["aciclovir", "SIMPLE_CHEMICAL", 161, 170], ["Patients", "SPECIES", 0, 8], ["Pneumocystis jiroveci", "SPECIES", 71, 92], ["Pneumocystis jiroveci", "SPECIES", 71, 92], ["cyclosporine", "TREATMENT", 18, 30], ["GvHD prophylaxis", "TREATMENT", 35, 51], ["cotrimoxazole", "TREATMENT", 53, 66], ["Pneumocystis jiroveci prophylaxis", "TREATMENT", 71, 104], ["liposomal amphotericin", "TREATMENT", 106, 128], ["antifungal prophylaxis", "TREATMENT", 133, 155], ["aciclovir", "TREATMENT", 161, 170], ["antiviral prophylaxis", "TREATMENT", 175, 196], ["Pneumocystis jiroveci", "OBSERVATION", 71, 92]]], ["Patients received blood and platelet support and granulocyte colony stimulating factor until engraftment, at the discretion of the managing physician.", [["blood", "ANATOMY", 18, 23], ["platelet", "ANATOMY", 28, 36], ["Patients", "ORGANISM", 0, 8], ["blood", "ORGANISM_SUBSTANCE", 18, 23], ["platelet", "CELL", 28, 36], ["granulocyte colony stimulating factor", "GENE_OR_GENE_PRODUCT", 49, 86], ["granulocyte colony stimulating factor", "PROTEIN", 49, 86], ["Patients", "SPECIES", 0, 8], ["blood", "TREATMENT", 18, 23], ["platelet support", "TREATMENT", 28, 44], ["granulocyte colony stimulating factor", "TREATMENT", 49, 86]]], ["All parents gave written consent according to our local centre and European Blood and Marrow transplantation guidelines.Immunological StudiesTime to neutrophil (third consecutive day of absolute neutrophil count (ANC) > .5 \u00c2 10 9 /L), platelet (platelet count of >50 \u00c2 10 9 /L independent of transfusion support) and T lymphocyte (first day of a CD3 \u00fe count > 200 cells/mL) engraftment was recorded.", [["Blood", "ANATOMY", 76, 81], ["Marrow", "ANATOMY", 86, 92], ["neutrophil", "ANATOMY", 149, 159], ["neutrophil", "ANATOMY", 195, 205], ["platelet", "ANATOMY", 235, 243], ["platelet", "ANATOMY", 245, 253], ["T lymphocyte", "ANATOMY", 317, 329], ["cells", "ANATOMY", 364, 369], ["Blood", "ORGANISM_SUBSTANCE", 76, 81], ["Marrow", "TISSUE", 86, 92], ["neutrophil", "CELL", 149, 159], ["neutrophil", "CELL", 195, 205], ["platelet", "CELL", 235, 243], ["platelet", "CELL", 245, 253], ["T lymphocyte", "CELL", 317, 329], ["CD3", "GENE_OR_GENE_PRODUCT", 346, 349], ["neutrophil", "CELL_TYPE", 149, 159], ["platelet", "CELL_TYPE", 235, 243], ["T lymphocyte", "CELL_TYPE", 317, 329], ["CD3", "PROTEIN", 346, 349], ["Marrow transplantation guidelines", "TREATMENT", 86, 119], ["neutrophil", "TEST", 149, 159], ["absolute neutrophil count", "TEST", 186, 211], ["ANC", "TEST", 213, 216], ["platelet", "TEST", 235, 243], ["platelet count", "TEST", 245, 259], ["transfusion support", "TREATMENT", 292, 311], ["T lymphocyte", "TEST", 317, 329], ["a CD3 \u00fe count", "TEST", 344, 357], ["engraftment", "TEST", 374, 385], ["Marrow transplantation", "OBSERVATION", 86, 108]]], ["Lymphocyte subset analysis was measured by 4-color flow cytometry as previously described [26] .", [["Lymphocyte", "ANATOMY", 0, 10], ["Lymphocyte", "CELL", 0, 10], ["Lymphocyte subset analysis", "TEST", 0, 26], ["color flow cytometry", "TEST", 45, 65]]], ["Briefly, lymphocyte surface marker studies were performed on fresh whole blood collected in EDTA using appropriate markers (CD45 PerCP, CD3 FITC, CD4 APC, CD8 PE, CD19 APC, CD16/CD56 PE, CD3 PerCP/CD4 APC/CD45RAFITC/ CD27 PE, CD19 PerCP/CD27 FITC/IgM APC/IgD PE [Becton Dickinson, UK Ltd, Oxford]), and analyzed on a Becton Dickinson FACS Calibur flow cytometer.", [["lymphocyte surface", "ANATOMY", 9, 27], ["whole blood", "ANATOMY", 67, 78], ["EDTA", "CHEMICAL", 92, 96], ["FITC", "CHEMICAL", 140, 144], ["FITC", "CHEMICAL", 242, 246], ["lymphocyte", "CELL", 9, 19], ["blood", "ORGANISM_SUBSTANCE", 73, 78], ["EDTA", "SIMPLE_CHEMICAL", 92, 96], ["CD45", "GENE_OR_GENE_PRODUCT", 124, 128], ["CD3 FITC", "GENE_OR_GENE_PRODUCT", 136, 144], ["CD4 APC", "GENE_OR_GENE_PRODUCT", 146, 153], ["CD8 PE", "GENE_OR_GENE_PRODUCT", 155, 161], ["CD19 APC", "GENE_OR_GENE_PRODUCT", 163, 171], ["CD16", "GENE_OR_GENE_PRODUCT", 173, 177], ["CD56", "GENE_OR_GENE_PRODUCT", 178, 182], ["CD3", "GENE_OR_GENE_PRODUCT", 187, 190], ["CD4 APC", "GENE_OR_GENE_PRODUCT", 197, 204], ["CD27", "GENE_OR_GENE_PRODUCT", 217, 221], ["CD19", "GENE_OR_GENE_PRODUCT", 226, 230], ["CD27 FITC", "GENE_OR_GENE_PRODUCT", 237, 246], ["IgM APC", "GENE_OR_GENE_PRODUCT", 247, 254], ["CD45", "PROTEIN", 124, 128], ["PerCP", "PROTEIN", 129, 134], ["CD3 FITC", "PROTEIN", 136, 144], ["CD4 APC", "PROTEIN", 146, 153], ["CD8 PE", "PROTEIN", 155, 161], ["CD19 APC", "PROTEIN", 163, 171], ["CD16", "PROTEIN", 173, 177], ["CD56 PE", "PROTEIN", 178, 185], ["CD3", "PROTEIN", 187, 190], ["PerCP", "PROTEIN", 191, 196], ["CD4", "PROTEIN", 197, 200], ["APC", "PROTEIN", 201, 204], ["CD45RAFITC", "PROTEIN", 205, 215], ["CD27 PE", "PROTEIN", 217, 224], ["CD19", "PROTEIN", 226, 230], ["PerCP", "PROTEIN", 231, 236], ["CD27 FITC", "PROTEIN", 237, 246], ["IgM APC", "PROTEIN", 247, 254], ["IgD PE", "PROTEIN", 255, 261], ["lymphocyte surface marker studies", "TEST", 9, 42], ["appropriate markers", "TEST", 103, 122], ["CD45", "TEST", 124, 128], ["PerCP", "TEST", 129, 134], ["CD3 FITC", "TEST", 136, 144], ["CD4 APC", "TEST", 146, 153], ["CD8 PE", "PROBLEM", 155, 161], ["CD19", "TEST", 163, 167], ["APC", "TEST", 168, 171], ["CD16", "TEST", 173, 177], ["CD56", "TEST", 178, 182], ["PE", "TEST", 183, 185], ["CD3", "TEST", 187, 190], ["PerCP", "TEST", 191, 196], ["CD4", "TEST", 197, 200], ["APC", "TEST", 201, 204], ["CD45RAFITC", "TEST", 205, 215], ["PE", "PROBLEM", 222, 224], ["CD19", "TEST", 226, 230], ["PerCP", "TEST", 231, 236], ["CD27 FITC", "TEST", 237, 246], ["APC", "PROBLEM", 251, 254], ["IgD PE", "PROBLEM", 255, 261], ["CD19 APC", "OBSERVATION", 163, 171], ["PE", "OBSERVATION", 259, 261]]], ["The markers CD4 \u00fe /CD45RA \u00fe and CD4 \u00fe /CD45RA \u00fe /CD27 \u00fe were used as surrogates for early thymic emigrant equivalents (ETEEs) [27] .", [["CD4 \u00fe /CD45RA \u00fe", "ANATOMY", 12, 27], ["CD4 \u00fe /CD45RA \u00fe /CD27 \u00fe", "ANATOMY", 32, 55], ["thymic emigrant", "ANATOMY", 90, 105], ["CD4", "GENE_OR_GENE_PRODUCT", 12, 15], ["CD45", "GENE_OR_GENE_PRODUCT", 19, 23], ["CD4", "GENE_OR_GENE_PRODUCT", 32, 35], ["CD45RA", "GENE_OR_GENE_PRODUCT", 39, 45], ["CD27", "GENE_OR_GENE_PRODUCT", 49, 53], ["CD4", "PROTEIN", 12, 15], ["CD45", "PROTEIN", 19, 23], ["CD4", "PROTEIN", 32, 35], ["CD45RA", "PROTEIN", 39, 45], ["CD27", "PROTEIN", 49, 53], ["The markers", "TEST", 0, 11], ["CD4", "TEST", 12, 15], ["CD45", "TEST", 19, 23], ["RA", "TEST", 23, 25], ["\u00fe", "TEST", 26, 27], ["CD4", "TEST", 32, 35], ["CD45RA", "TEST", 39, 45]]], ["Lymphocyte subsets (CD3 \u00fe , CD4 \u00fe , CD8 \u00fe , CD19 \u00fe , natural killer [NK] cells and CD4 \u00fe ETEEs) at 2, 4, 6, and 12 months follow-up were recorded.", [["Lymphocyte", "ANATOMY", 0, 10], ["CD3 \u00fe", "ANATOMY", 20, 25], ["CD4 \u00fe", "ANATOMY", 28, 33], ["CD8 \u00fe , CD19 \u00fe", "ANATOMY", 36, 50], ["natural killer [NK] cells", "ANATOMY", 53, 78], ["CD4 \u00fe ETEEs", "ANATOMY", 83, 94], ["Lymphocyte", "CELL", 0, 10], ["CD3", "GENE_OR_GENE_PRODUCT", 20, 23], ["CD4", "GENE_OR_GENE_PRODUCT", 28, 31], ["CD8", "GENE_OR_GENE_PRODUCT", 36, 39], ["CD19", "GENE_OR_GENE_PRODUCT", 44, 48], ["CD4", "GENE_OR_GENE_PRODUCT", 83, 86], ["Lymphocyte subsets", "CELL_TYPE", 0, 18], ["CD3", "PROTEIN", 20, 23], ["CD4", "PROTEIN", 28, 31], ["CD8", "PROTEIN", 36, 39], ["CD19", "PROTEIN", 44, 48], ["natural killer [NK] cells", "CELL_TYPE", 53, 78], ["CD4", "PROTEIN", 83, 86], ["Lymphocyte subsets", "TEST", 0, 18], ["CD3", "TEST", 20, 23], ["\u00fe", "TEST", 24, 25], ["CD4", "TEST", 28, 31], ["\u00fe", "TEST", 32, 33], ["CD8", "TEST", 36, 39], ["\u00fe", "TEST", 40, 41], ["CD19", "TEST", 44, 48], ["\u00fe", "TEST", 49, 50], ["natural killer", "TEST", 53, 67], ["cells", "TEST", 73, 78], ["CD4", "TEST", 83, 86], ["ETEEs", "TEST", 89, 94]]], ["Specific antibody responses to pneumococcal (polysaccharide or Prevenar), tetanus toxoid and Haemophilus influenzae b vaccine antigens were measured by ELISA and defined as present or absent after vaccination [28] .Chimerism StudiesWhole blood was stained with CD3, CD19, or CD15 micro beads and cell lines were separated using an autoMACS automated bench-top magnetic cell sorter (Miltenyi Biotec Ltd, Surrey, UK).", [["blood", "ANATOMY", 238, 243], ["cell lines", "ANATOMY", 296, 306], ["cell", "ANATOMY", 369, 373], ["Prevenar", "CHEMICAL", 63, 71], ["tetanus toxoid", "DISEASE", 74, 88], ["pneumococcal", "ORGANISM", 31, 43], ["Prevenar", "SIMPLE_CHEMICAL", 63, 71], ["tetanus toxoid", "ORGANISM", 74, 88], ["Haemophilus influenzae b", "ORGANISM", 93, 117], ["blood", "ORGANISM_SUBSTANCE", 238, 243], ["CD3", "GENE_OR_GENE_PRODUCT", 261, 264], ["CD19", "GENE_OR_GENE_PRODUCT", 266, 270], ["CD15", "GENE_OR_GENE_PRODUCT", 275, 279], ["cell lines", "CELL", 296, 306], ["CD3", "PROTEIN", 261, 264], ["CD19", "PROTEIN", 266, 270], ["cell lines", "CELL_LINE", 296, 306], ["bench-top magnetic cell sorter", "CELL_LINE", 350, 380], ["Miltenyi Biotec", "PROTEIN", 382, 397], ["tetanus toxoid", "SPECIES", 74, 88], ["Haemophilus influenzae", "SPECIES", 93, 115], ["pneumococcal", "SPECIES", 31, 43], ["Haemophilus influenzae", "SPECIES", 93, 115], ["Specific antibody responses", "TEST", 0, 27], ["pneumococcal (polysaccharide", "TREATMENT", 31, 59], ["Prevenar)", "TREATMENT", 63, 72], ["tetanus toxoid", "TREATMENT", 74, 88], ["Haemophilus influenzae b vaccine antigens", "TREATMENT", 93, 134], ["Chimerism Studies", "TEST", 215, 232], ["Whole blood", "TEST", 232, 243], ["CD3", "TEST", 261, 264], ["CD19", "TEST", 266, 270], ["CD15 micro beads", "TEST", 275, 291], ["cell lines", "TREATMENT", 296, 306], ["an autoMACS automated bench", "TEST", 328, 355], ["cell lines", "OBSERVATION", 296, 306], ["cell sorter", "OBSERVATION", 369, 380]]], ["Chimerism was measured in sexmismatched cases by XY-fluorescent in-situ hybridization (FISH) using standard cytogenetic techniques.", [["Chimerism", "TEST", 0, 9], ["standard cytogenetic techniques", "TEST", 99, 130]]], ["Briefly, interphase FISH was performed using a Vysis 2-color CEP X/CEP Y probe set according to the manufacturer's protocol.", [["interphase", "CELLULAR_COMPONENT", 9, 19], ["Vysis 2-color CEP X/CEP Y probe", "DNA", 47, 78], ["a Vysis 2-color CEP X/CEP Y probe", "TREATMENT", 45, 78], ["the manufacturer's protocol", "TREATMENT", 96, 123]]], ["Where donor and recipient were same sex, chimerism was measured by short tandem repeat marker analysis of genomic DNA, as previously described [29] .", [["DNA", "CELLULAR_COMPONENT", 114, 117], ["genomic DNA", "DNA", 106, 117], ["short tandem repeat marker analysis", "TEST", 67, 102], ["genomic DNA", "PROBLEM", 106, 117], ["genomic DNA", "OBSERVATION", 106, 117]]], ["Most recent donor chimerism for T cell, B cell, and myeloid lineages was recorded.", [["T cell", "ANATOMY", 32, 38], ["B cell", "ANATOMY", 40, 46], ["myeloid", "ANATOMY", 52, 59], ["T cell", "CELL", 32, 38], ["B cell", "CELL", 40, 46], ["myeloid lineages", "CELL", 52, 68], ["T cell", "CELL_TYPE", 32, 38], ["B cell", "CELL_TYPE", 40, 46], ["myeloid lineages", "CELL_TYPE", 52, 68], ["T cell", "PROBLEM", 32, 38], ["myeloid lineages", "PROBLEM", 52, 68], ["myeloid lineages", "OBSERVATION", 52, 68]]], ["Chimerism was defined as donor (>95% donor cells), high-level mixed (50% to 95% donor cells), mixed (5% to 49% donor cells) or recipient (<5% donor cells) in specific cell lineages.Viral ClearancePatients were considered to have viral infection when a positive virology result by PCR, tissue culture, electron microscopy, or immuno-chromogenic methods was present.", [["cells", "ANATOMY", 43, 48], ["cells", "ANATOMY", 86, 91], ["cells", "ANATOMY", 117, 122], ["cells", "ANATOMY", 148, 153], ["cell", "ANATOMY", 167, 171], ["tissue", "ANATOMY", 285, 291], ["viral infection", "DISEASE", 229, 244], ["cells", "CELL", 43, 48], ["cells", "CELL", 86, 91], ["cells", "CELL", 117, 122], ["cells", "CELL", 148, 153], ["cell", "CELL", 167, 171], ["Viral", "ORGANISM", 181, 186], ["tissue", "TISSUE", 285, 291], ["donor cells", "CELL_TYPE", 37, 48], ["donor cells", "CELL_TYPE", 80, 91], ["donor cells", "CELL_TYPE", 111, 122], ["donor cells", "CELL_TYPE", 142, 153], ["specific cell lineages", "CELL_TYPE", 158, 180], ["Chimerism", "TEST", 0, 9], ["donor", "TEST", 25, 30], ["donor cells", "TEST", 37, 48], ["donor cells", "TEST", 80, 91], ["donor cells", "TEST", 111, 122], ["donor cells", "TEST", 142, 153], ["viral infection", "PROBLEM", 229, 244], ["PCR", "TEST", 280, 283], ["tissue culture", "TEST", 285, 299], ["electron microscopy", "TEST", 301, 320], ["immuno-chromogenic methods", "TEST", 325, 351], ["specific cell lineages", "OBSERVATION", 158, 180], ["infection", "OBSERVATION", 235, 244]]], ["Viral PCR for adenovirus, cytomegalovirus, human herpes virus 6, Epstein-Barr virus, enterovirus, parainfluenza virus 3, respiratory syncytial virus, coronavirus, astrovirus, varicella-zoster virus, and norovirus; electron microscopy for small round structured virus, coronavirus, norovirus, astrovirus, and rotavirus; tissue culture for poliovirus vaccine strains; and immuno-chromogenic methods for adenovirus and rotavirus were undertaken at Newcastle Health Protection Agency Laboratories, Newcastle, United Kingdom.", [["tissue", "ANATOMY", 319, 325], ["parainfluenza virus", "DISEASE", 98, 117], ["respiratory syncytial virus", "DISEASE", 121, 148], ["astrovirus", "DISEASE", 163, 173], ["varicella-zoster virus", "DISEASE", 175, 197], ["norovirus, astrovirus", "DISEASE", 281, 302], ["adenovirus", "ORGANISM", 14, 24], ["cytomegalovirus", "ORGANISM", 26, 41], ["human herpes virus 6", "ORGANISM", 43, 63], ["Epstein-Barr virus", "ORGANISM", 65, 83], ["enterovirus", "ORGANISM", 85, 96], ["parainfluenza virus 3", "ORGANISM", 98, 119], ["respiratory syncytial virus", "ORGANISM", 121, 148], ["coronavirus", "ORGANISM", 150, 161], ["astrovirus", "ORGANISM", 163, 173], ["varicella-zoster virus", "ORGANISM", 175, 197], ["coronavirus", "ORGANISM", 268, 279], ["norovirus", "ORGANISM", 281, 290], ["astrovirus", "ORGANISM", 292, 302], ["rotavirus", "ORGANISM", 308, 317], ["tissue", "TISSUE", 319, 325], ["poliovirus", "ORGANISM", 338, 348], ["adenovirus", "ORGANISM", 401, 411], ["rotavirus", "ORGANISM", 416, 425], ["human", "SPECIES", 43, 48], ["herpes virus", "SPECIES", 49, 61], ["Barr virus", "SPECIES", 73, 83], ["parainfluenza virus 3", "SPECIES", 98, 119], ["respiratory syncytial virus", "SPECIES", 121, 148], [", coronavirus", "SPECIES", 148, 161], ["astrovirus", "SPECIES", 163, 173], ["varicella-zoster virus", "SPECIES", 175, 197], ["coronavirus", "SPECIES", 268, 279], ["rotavirus", "SPECIES", 308, 317], ["adenovirus", "SPECIES", 14, 24], ["human herpes virus", "SPECIES", 43, 61], ["Epstein-Barr virus", "SPECIES", 65, 83], ["parainfluenza virus", "SPECIES", 98, 117], ["respiratory syncytial virus", "SPECIES", 121, 148], ["varicella-zoster virus", "SPECIES", 175, 197], ["rotavirus", "SPECIES", 308, 317], ["adenovirus", "SPECIES", 401, 411], ["rotavirus", "SPECIES", 416, 425], ["Viral PCR", "TEST", 0, 9], ["adenovirus", "PROBLEM", 14, 24], ["cytomegalovirus", "PROBLEM", 26, 41], ["human herpes virus", "TEST", 43, 61], ["Epstein", "TEST", 65, 72], ["Barr virus", "PROBLEM", 73, 83], ["enterovirus", "PROBLEM", 85, 96], ["parainfluenza virus", "PROBLEM", 98, 117], ["respiratory syncytial virus", "PROBLEM", 121, 148], ["coronavirus", "PROBLEM", 150, 161], ["astrovirus", "PROBLEM", 163, 173], ["varicella", "PROBLEM", 175, 184], ["zoster virus", "PROBLEM", 185, 197], ["norovirus", "PROBLEM", 203, 212], ["electron microscopy", "TEST", 214, 233], ["small round structured virus", "PROBLEM", 238, 266], ["coronavirus", "PROBLEM", 268, 279], ["norovirus", "PROBLEM", 281, 290], ["astrovirus", "PROBLEM", 292, 302], ["rotavirus", "PROBLEM", 308, 317], ["tissue culture", "TEST", 319, 333], ["poliovirus vaccine strains", "TREATMENT", 338, 364], ["immuno-chromogenic methods", "TREATMENT", 370, 396], ["adenovirus", "PROBLEM", 401, 411], ["rotavirus", "PROBLEM", 416, 425], ["respiratory syncytial", "ANATOMY", 121, 142], ["zoster virus", "OBSERVATION", 185, 197]]], ["Viral infections were considered cleared on the first of 3 consecutively negative virology results.", [["Viral infections", "DISEASE", 0, 16], ["Viral", "ORGANISM", 0, 5], ["Viral infections", "PROBLEM", 0, 16], ["infections", "OBSERVATION", 6, 16]]], ["If there was recurrence of the same infection at a later date, this was treated as failure to clear the virus.", [["infection", "DISEASE", 36, 45], ["the same infection", "PROBLEM", 27, 45], ["the virus", "PROBLEM", 100, 109], ["infection", "OBSERVATION", 36, 45], ["virus", "OBSERVATION", 104, 109]]], ["Viral infection was considered present if the patient died with most recent result being positive or if there was still virological evidence of infection at last follow-up.GvHD, Mortality and Follow-upGvHD grade, target organ, and whether it was acute or chronic were recorded.", [["organ", "ANATOMY", 220, 225], ["Viral infection", "DISEASE", 0, 15], ["infection", "DISEASE", 144, 153], ["GvHD", "DISEASE", 172, 176], ["Viral", "ORGANISM", 0, 5], ["patient", "ORGANISM", 46, 53], ["organ", "ORGAN", 220, 225], ["patient", "SPECIES", 46, 53], ["Viral infection", "PROBLEM", 0, 15], ["infection", "PROBLEM", 144, 153], ["GvHD", "PROBLEM", 172, 176], ["Follow-upGvHD grade", "TEST", 192, 211], ["acute or chronic", "PROBLEM", 246, 262], ["infection", "OBSERVATION", 6, 15], ["infection", "OBSERVATION", 144, 153], ["organ", "ANATOMY", 220, 225], ["acute", "OBSERVATION_MODIFIER", 246, 251], ["chronic", "OBSERVATION_MODIFIER", 255, 262]]], ["GvHD was defined by modified Glucksberg criteria.", [["GvHD", "DISEASE", 0, 4], ["GvHD", "PROBLEM", 0, 4]]], ["Time to death and cause of death were recorded.", [["death", "DISEASE", 8, 13], ["death", "DISEASE", 27, 32], ["death", "PROBLEM", 27, 32]]], ["Transplantation-related mortality (TRM) was defined as cause of death as a direct result of the transplantation procedure.", [["death", "DISEASE", 64, 69], ["Transplantation", "TREATMENT", 0, 15], ["death", "PROBLEM", 64, 69], ["the transplantation procedure", "TREATMENT", 92, 121], ["transplantation", "OBSERVATION", 96, 111]]], ["Time to most recent follow-up and independence of replacement immunoglobulin were recorded.", [["immunoglobulin", "GENE_OR_GENE_PRODUCT", 62, 76], ["immunoglobulin", "PROTEIN", 62, 76], ["replacement immunoglobulin", "TREATMENT", 50, 76]]], ["Supplementary Table S1 .Statistical AnalysisDifferences between high-and low-dose serotherapy were analyzed.", [["Statistical AnalysisDifferences", "TEST", 24, 55], ["low-dose serotherapy", "TREATMENT", 73, 93], ["S1", "ANATOMY", 20, 22], ["high", "OBSERVATION_MODIFIER", 64, 68]]], ["Fisher's exact and Mann-Whitney U tests were performed using SAS 9.2 for Windows (SAS Institute Inc., Cary, NC).", [["Whitney U tests", "TEST", 24, 39], ["SAS", "TEST", 61, 64]]], ["Kaplan-Meier survival analysis, 95% confidence intervals, and log-rank test were performed using SPSS Statistics 19 (IBM SPSS, Armonk, NY).", [["log-rank test", "TEST", 62, 75], ["SPSS Statistics", "TEST", 97, 112]]], ["All tests were considered statistically significant if P < .05.Transplantation Characteristics and Serotherapy DoseDemographics and transplantation characteristics are summarized in Table 1 .", [["All tests", "TEST", 0, 9], ["Transplantation", "TREATMENT", 63, 78], ["Serotherapy DoseDemographics", "TREATMENT", 99, 127]]], ["All patients were 12 months of age or younger at transplantation.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12]]], ["Only year of transplantation was significantly different between high-dose and low-dose serotherapy groups (P \u00bc .001).", [["transplantation", "TREATMENT", 13, 28], ["low-dose serotherapy groups", "TREATMENT", 79, 106], ["transplantation", "OBSERVATION", 13, 28]]], ["Low-dose serotherapy CBT all occurred after 2006, whereas high-dose serotherapy CBT mainly occurred before 2006, consistent with the systematic change in practice.EngraftmentNeutrophil engraftment was similar for high-and lowdose serotherapy (P \u00bc .675), with median engraftment occurring at 21 days (range, 13 to 38) and 20 days (range, 15 to 31), respectively.", [["Neutrophil", "ANATOMY", 174, 184], ["Neutrophil", "CELL", 174, 184], ["Low-dose serotherapy CBT", "TREATMENT", 0, 24], ["high-dose serotherapy CBT", "TREATMENT", 58, 83], ["EngraftmentNeutrophil engraftment", "TREATMENT", 163, 196], ["median engraftment", "TREATMENT", 259, 277], ["Neutrophil engraftment", "OBSERVATION", 174, 196], ["median engraftment", "OBSERVATION", 259, 277]]], ["Platelet engraftment occurred at a median of 38 days (range, 18 to 114) and 31 days (range, 0 to 46) for the high-and low-dose serotherapy groups respectively (P \u00bc .095).", [["Platelet", "ANATOMY", 0, 8], ["Platelet", "CELL", 0, 8], ["Platelet engraftment", "TEST", 0, 20], ["low-dose serotherapy groups", "TREATMENT", 118, 145], ["engraftment", "OBSERVATION", 9, 20]]], ["Platelet engraftment took over 100 days in 1 patient in the high-dose serotherapy group.Lymphocyte ReconstitutionCD3 \u00fe lymphocyte engraftment occurred at a median time of 92.5 days (range, 56 to 222) and 97 days (range, 14 to 107) for high-and low-dose serotherapy, respectively (P \u00bc .171).Lymphocyte ReconstitutionT lymphocyte counts increased throughout the first 12 months post CBT across the different T lymphocyte subsets (Table 2, Figure 1A -D).", [["Platelet", "ANATOMY", 0, 8], ["Lymphocyte", "ANATOMY", 88, 98], ["lymphocyte", "ANATOMY", 119, 129], ["Lymphocyte", "ANATOMY", 290, 300], ["lymphocyte", "ANATOMY", 317, 327], ["T lymphocyte", "ANATOMY", 406, 418], ["Platelet", "CELL", 0, 8], ["patient", "ORGANISM", 45, 52], ["Lymphocyte", "CELL", 88, 98], ["lymphocyte", "CELL", 119, 129], ["Lymphocyte", "CELL", 290, 300], ["lymphocyte", "CELL", 317, 327], ["T lymphocyte", "CELL", 406, 418], ["T lymphocyte subsets", "CELL_TYPE", 406, 426], ["patient", "SPECIES", 45, 52], ["Platelet engraftment", "TEST", 0, 20], ["the high-dose serotherapy group", "TREATMENT", 56, 87], ["Lymphocyte ReconstitutionCD3", "TEST", 88, 116], ["lymphocyte engraftment", "PROBLEM", 119, 141], ["low-dose serotherapy", "TREATMENT", 244, 264], ["Lymphocyte ReconstitutionT lymphocyte counts", "TEST", 290, 334], ["CBT", "TEST", 381, 384], ["lymphocyte engraftment", "OBSERVATION", 119, 141], ["lymphocyte counts", "OBSERVATION", 317, 334], ["increased", "OBSERVATION_MODIFIER", 335, 344], ["lymphocyte subsets", "OBSERVATION", 408, 426]]], ["Reconstitution was similar at 2 months for high-and low-dose serotherapy groups for all T lymphocyte subsets.", [["T lymphocyte", "ANATOMY", 88, 100], ["T lymphocyte", "CELL", 88, 100], ["T lymphocyte subsets", "CELL_TYPE", 88, 108], ["low-dose serotherapy groups", "TREATMENT", 52, 79], ["all T lymphocyte subsets", "TREATMENT", 84, 108], ["lymphocyte subsets", "OBSERVATION", 90, 108]]], ["At 4 months the low-dose serotherapy group had significantly higher CD3 \u00fe , CD4 \u00fe , and CD4 \u00fe ETEE counts, as compared with the high-dose group (P \u00bc .037, P \u00bc .037 and P \u00bc .021 respectively).", [["CD3", "GENE_OR_GENE_PRODUCT", 68, 71], ["CD4", "GENE_OR_GENE_PRODUCT", 76, 79], ["CD4", "GENE_OR_GENE_PRODUCT", 88, 91], ["ETEE", "GENE_OR_GENE_PRODUCT", 94, 98], ["CD3", "PROTEIN", 68, 71], ["CD4", "PROTEIN", 76, 79], ["CD4", "PROTEIN", 88, 91], ["the low-dose serotherapy group", "TREATMENT", 12, 42], ["CD4 \u00fe", "TEST", 76, 81], ["CD4", "TEST", 88, 91], ["ETEE counts", "TEST", 94, 105], ["P", "TEST", 155, 156], ["P", "TEST", 168, 169]]], ["CD4 \u00fe ETEE reconstitution followed a similar trend to CD4 \u00fe reconstitution ( Figure 1D ).", [["CD4", "GENE_OR_GENE_PRODUCT", 0, 3], ["CD4", "GENE_OR_GENE_PRODUCT", 54, 57], ["CD4", "PROTEIN", 0, 3], ["ETEE", "PROTEIN", 6, 10], ["CD4", "PROTEIN", 54, 57], ["CD4", "TEST", 0, 3], ["ETEE reconstitution", "TREATMENT", 6, 25], ["CD4 \u00fe reconstitution", "TREATMENT", 54, 74]]], ["By 6 and 12 months, CD3 \u00fe , CD4 \u00fe , and CD4 \u00fe ETEE cell reconstitution in the high-dose group was similar to lowdose group.", [["CD4 \u00fe", "ANATOMY", 28, 33], ["CD4 \u00fe ETEE cell", "ANATOMY", 40, 55], ["CD3", "GENE_OR_GENE_PRODUCT", 20, 23], ["CD4", "GENE_OR_GENE_PRODUCT", 28, 31], ["CD4", "GENE_OR_GENE_PRODUCT", 40, 43], ["lowdose", "SIMPLE_CHEMICAL", 109, 116], ["CD3", "PROTEIN", 20, 23], ["CD4", "PROTEIN", 28, 31], ["CD4", "PROTEIN", 40, 43], ["CD3", "TEST", 20, 23], ["CD4", "TEST", 28, 31], ["CD4", "TEST", 40, 43], ["ETEE cell reconstitution", "TREATMENT", 46, 70], ["the high-dose group", "TREATMENT", 74, 93], ["CD4", "ANATOMY", 40, 43], ["cell reconstitution", "OBSERVATION", 51, 70]]], ["CD8 \u00fe lymphocyte reconstitution was similar for high-and low-dose serotherapy groups throughout the first 12 months after CBT.Lymphocyte ReconstitutionB lymphocyte counts showed a trend of increasing in number over the first 12 months post CBT for both high-and low-dose serotherapy.", [["CD8 \u00fe lymphocyte", "ANATOMY", 0, 16], ["Lymphocyte", "ANATOMY", 126, 136], ["lymphocyte", "ANATOMY", 153, 163], ["CD8", "GENE_OR_GENE_PRODUCT", 0, 3], ["lymphocyte", "CELL", 6, 16], ["Lymphocyte", "CELL", 126, 136], ["lymphocyte", "CELL", 153, 163], ["CD8", "PROTEIN", 0, 3], ["CD8", "TEST", 0, 3], ["lymphocyte reconstitution", "TEST", 6, 31], ["low-dose serotherapy groups", "TREATMENT", 57, 84], ["CBT", "TEST", 122, 125], ["Lymphocyte ReconstitutionB lymphocyte counts", "TEST", 126, 170], ["CBT", "TEST", 240, 243], ["low-dose serotherapy", "TREATMENT", 262, 282], ["lymphocyte reconstitution", "OBSERVATION", 6, 31], ["trend", "OBSERVATION_MODIFIER", 180, 185], ["increasing", "OBSERVATION_MODIFIER", 189, 199]]], ["There was no significant difference in B cell reconstitution between high-and low-dose serotherapy groups (Table 2, Figure 1E ).", [["B cell", "ANATOMY", 39, 45], ["B cell", "CELL", 39, 45], ["significant difference", "PROBLEM", 13, 35], ["B cell reconstitution", "TREATMENT", 39, 60], ["high-and low-dose serotherapy groups", "TREATMENT", 69, 105], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["difference", "OBSERVATION_MODIFIER", 25, 35], ["B cell reconstitution", "OBSERVATION", 39, 60], ["high", "OBSERVATION_MODIFIER", 69, 73]]], ["NK cell counts were significantly higher at 2 months (P \u00bc .006) for high-dose serotherapy as compared with low-dose serotherapy.", [["NK cell", "ANATOMY", 0, 7], ["NK cell", "CELL", 0, 7], ["NK cell counts", "TEST", 0, 14], ["P", "TEST", 54, 55], ["high-dose serotherapy", "TREATMENT", 68, 89], ["low-dose serotherapy", "TREATMENT", 107, 127]]], ["At 4, 6, and 12 months, there was no significant difference in NK cell counts between serotherapy groups (Table 2, Figure 1F ).Viral ClearanceSeven patients had at least 1 viral infection at time of CBT and 7 patients contracted at least 1 viral infection post transplantation.", [["NK cell", "ANATOMY", 63, 70], ["viral infection", "DISEASE", 172, 187], ["viral infection", "DISEASE", 240, 255], ["NK cell", "CELL", 63, 70], ["patients", "ORGANISM", 148, 156], ["patients", "ORGANISM", 209, 217], ["patients", "SPECIES", 148, 156], ["patients", "SPECIES", 209, 217], ["significant difference", "PROBLEM", 37, 59], ["serotherapy groups", "TREATMENT", 86, 104], ["1 viral infection", "PROBLEM", 170, 187], ["CBT", "TEST", 199, 202], ["1 viral infection", "PROBLEM", 238, 255], ["transplantation", "TREATMENT", 261, 276], ["no", "UNCERTAINTY", 34, 36], ["significant", "OBSERVATION_MODIFIER", 37, 48], ["difference", "OBSERVATION_MODIFIER", 49, 59], ["NK cell counts", "OBSERVATION", 63, 77], ["viral", "OBSERVATION_MODIFIER", 172, 177], ["infection", "OBSERVATION", 178, 187], ["viral", "OBSERVATION_MODIFIER", 240, 245], ["infection", "OBSERVATION", 246, 255]]], ["Of these, 9 patients achieved clearance of all virus and a further 3 patients had insufficient data to determine achievement of viral clearance.", [["patients", "ORGANISM", 12, 20], ["patients", "ORGANISM", 69, 77], ["patients", "SPECIES", 12, 20], ["patients", "SPECIES", 69, 77], ["all virus", "PROBLEM", 43, 52], ["viral clearance", "PROBLEM", 128, 143], ["viral", "OBSERVATION", 128, 133]]], ["There was no difference in the number of viral infections present at CBT or new viral infection after CBT between high-and low-dose serotherapy groups.", [["viral infections", "DISEASE", 41, 57], ["viral infection", "DISEASE", 80, 95], ["viral infections", "PROBLEM", 41, 57], ["CBT", "PROBLEM", 69, 72], ["new viral infection", "PROBLEM", 76, 95], ["CBT", "TEST", 102, 105], ["high", "TEST", 114, 118], ["low-dose serotherapy groups", "TREATMENT", 123, 150], ["no", "UNCERTAINTY", 10, 12], ["difference", "OBSERVATION_MODIFIER", 13, 23], ["viral", "OBSERVATION_MODIFIER", 41, 46], ["infections", "OBSERVATION", 47, 57], ["new", "OBSERVATION_MODIFIER", 76, 79], ["viral", "OBSERVATION_MODIFIER", 80, 85], ["infection", "OBSERVATION", 86, 95]]], ["All evaluable patients who received serotherapy cleared viral infections (Table 3 ).", [["viral infections", "DISEASE", 56, 72], ["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["serotherapy", "TREATMENT", 36, 47], ["viral infections", "PROBLEM", 56, 72]]], ["There were insufficient results to analyze the time to viral clearance further.Chimerism and Graft FunctionThere was no significant difference in donor chimerism between high-dose and low-dose serotherapy in any of the 3 cell lineages (Figure 2 ).", [["Graft", "ANATOMY", 93, 98], ["cell", "ANATOMY", 221, 225], ["cell", "CELL", 221, 225], ["viral clearance", "TEST", 55, 70], ["Chimerism and Graft Function", "TREATMENT", 79, 107], ["significant difference in donor chimerism", "PROBLEM", 120, 161], ["low-dose serotherapy", "TREATMENT", 184, 204], ["Graft", "OBSERVATION", 93, 98], ["no", "UNCERTAINTY", 117, 119], ["significant", "OBSERVATION_MODIFIER", 120, 131], ["difference", "OBSERVATION_MODIFIER", 132, 142], ["donor chimerism", "OBSERVATION", 146, 161]]], ["One patient with Chronic Granulomatous Disease who received high-dose serotherapy has undergone a second HSCT for falling myeloid chimerism.Chimerism and Graft FunctionAll except 2 patients discontinued replacement immunoglobulin by 24 months and all those who have been vaccinated have responded to Haemophilus influenza b, tetanus toxoid, and pneumococcal vaccinations (Table 3) .", [["myeloid", "ANATOMY", 122, 129], ["Graft", "ANATOMY", 154, 159], ["Chronic Granulomatous Disease", "DISEASE", 17, 46], ["myeloid chimerism", "DISEASE", 122, 139], ["Haemophilus influenza b", "DISEASE", 300, 323], ["tetanus toxoid", "DISEASE", 325, 339], ["patient", "ORGANISM", 4, 11], ["myeloid", "CELL", 122, 129], ["patients", "ORGANISM", 181, 189], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 215, 229], ["Haemophilus influenza b", "ORGANISM", 300, 323], ["tetanus toxoid", "ORGANISM", 325, 339], ["immunoglobulin", "PROTEIN", 215, 229], ["patient", "SPECIES", 4, 11], ["patients", "SPECIES", 181, 189], ["Haemophilus influenza", "SPECIES", 300, 321], ["pneumococcal", "SPECIES", 345, 357], ["Chronic Granulomatous Disease", "PROBLEM", 17, 46], ["high-dose serotherapy", "TREATMENT", 60, 81], ["a second HSCT", "TREATMENT", 96, 109], ["falling myeloid chimerism", "PROBLEM", 114, 139], ["Chimerism and Graft Function", "TREATMENT", 140, 168], ["replacement immunoglobulin", "TREATMENT", 203, 229], ["Haemophilus influenza b", "TREATMENT", 300, 323], ["tetanus toxoid", "TREATMENT", 325, 339], ["pneumococcal vaccinations", "TREATMENT", 345, 370], ["Chronic", "OBSERVATION_MODIFIER", 17, 24], ["Granulomatous", "OBSERVATION", 25, 38], ["myeloid chimerism", "OBSERVATION", 122, 139], ["Graft", "OBSERVATION", 154, 159]]], ["Two patients who received high-dose serotherapy were dependent on immunoglobulin therapy to 32 and 34 months and have since made a good response to primary vaccinations.", [["patients", "ORGANISM", 4, 12], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 66, 80], ["immunoglobulin", "PROTEIN", 66, 80], ["patients", "SPECIES", 4, 12], ["high-dose serotherapy", "TREATMENT", 26, 47], ["immunoglobulin therapy", "TREATMENT", 66, 88], ["primary vaccinations", "TREATMENT", 148, 168]]], ["One patient in the low-dose serotherapy group has Mann-Whitney U P values stated for difference between high-and low-dose serotherapy and considered significant if P < .05.Chimerism and Graft Functiondiscontinued immunoglobulin but has not yet received primary vaccinations.GvHD and MortalityEight patients developed acute GvHD (40%); 5 grade II GvHD (25%).", [["GvHD", "DISEASE", 274, 278], ["MortalityEight", "DISEASE", 283, 297], ["GvHD", "DISEASE", 323, 327], ["GvHD", "DISEASE", 346, 350], ["patient", "ORGANISM", 4, 11], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 213, 227], ["patients", "ORGANISM", 298, 306], ["Graft Functiondiscontinued immunoglobulin", "PROTEIN", 186, 227], ["patient", "SPECIES", 4, 11], ["patients", "SPECIES", 298, 306], ["the low-dose serotherapy group", "TREATMENT", 15, 45], ["low-dose serotherapy", "TREATMENT", 113, 133], ["Chimerism", "TEST", 172, 181], ["Graft Functiondiscontinued immunoglobulin", "TREATMENT", 186, 227], ["primary vaccinations", "TREATMENT", 253, 273], ["GvHD", "PROBLEM", 274, 278], ["acute GvHD", "PROBLEM", 317, 327], ["5 grade II GvHD", "PROBLEM", 335, 350], ["Graft", "OBSERVATION", 186, 191], ["acute", "OBSERVATION_MODIFIER", 317, 322], ["GvHD", "OBSERVATION", 323, 327], ["GvHD", "OBSERVATION", 346, 350]]], ["No patients experienced grade IV GvHD.", [["GvHD", "DISEASE", 33, 37], ["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11], ["grade IV GvHD", "PROBLEM", 24, 37], ["grade IV", "OBSERVATION_MODIFIER", 24, 32], ["GvHD", "OBSERVATION", 33, 37]]], ["There was no statistically significant difference in the severity of GvHD between high-and low-dose serotherapy groups (P \u00bc .464; Table 3 ).", [["GvHD", "DISEASE", 69, 73], ["GvHD", "PROBLEM", 69, 73], ["high-and low-dose serotherapy groups", "TREATMENT", 82, 118], ["no", "UNCERTAINTY", 10, 12], ["statistically", "OBSERVATION_MODIFIER", 13, 26], ["significant", "OBSERVATION_MODIFIER", 27, 38], ["difference", "OBSERVATION_MODIFIER", 39, 49], ["GvHD", "OBSERVATION", 69, 73]]], ["One patient, who received high-dose serotherapy, developed chronic skin GvHD.GvHD and MortalityAll TRM occurred within 6 months of transplantation.", [["skin", "ANATOMY", 67, 71], ["skin GvHD", "DISEASE", 67, 76], ["GvHD", "DISEASE", 77, 81], ["patient", "ORGANISM", 4, 11], ["skin", "ORGAN", 67, 71], ["patient", "SPECIES", 4, 11], ["high-dose serotherapy", "TREATMENT", 26, 47], ["chronic skin GvHD", "PROBLEM", 59, 76], ["GvHD", "PROBLEM", 77, 81], ["MortalityAll TRM", "TREATMENT", 86, 102], ["transplantation", "TREATMENT", 131, 146], ["chronic", "OBSERVATION_MODIFIER", 59, 66], ["skin", "ANATOMY", 67, 71], ["GvHD", "OBSERVATION", 72, 76], ["MortalityAll TRM", "OBSERVATION", 86, 102]]], ["One patient who received high-dose chemotherapy died from TRM (possible veno-occlusive disease and gastrointestinal hemorrhage complicated by chronic lung disease).", [["veno-occlusive", "ANATOMY", 72, 86], ["gastrointestinal", "ANATOMY", 99, 115], ["lung", "ANATOMY", 150, 154], ["TRM", "DISEASE", 58, 61], ["veno-occlusive disease", "DISEASE", 72, 94], ["gastrointestinal hemorrhage", "DISEASE", 99, 126], ["chronic lung disease", "DISEASE", 142, 162], ["patient", "ORGANISM", 4, 11], ["gastrointestinal", "ORGAN", 99, 115], ["lung", "ORGAN", 150, 154], ["patient", "SPECIES", 4, 11], ["high-dose chemotherapy", "TREATMENT", 25, 47], ["TRM", "PROBLEM", 58, 61], ["veno-occlusive disease", "PROBLEM", 72, 94], ["gastrointestinal hemorrhage", "PROBLEM", 99, 126], ["chronic lung disease)", "PROBLEM", 142, 163], ["possible", "UNCERTAINTY", 63, 71], ["veno-occlusive", "OBSERVATION_MODIFIER", 72, 86], ["disease", "OBSERVATION", 87, 94], ["gastrointestinal", "ANATOMY", 99, 115], ["hemorrhage", "OBSERVATION", 116, 126], ["chronic", "OBSERVATION_MODIFIER", 142, 149], ["lung", "ANATOMY", 150, 154], ["disease", "OBSERVATION", 155, 162]]], ["Another patient who received high-dose serotherapy died from sudden infant death syndrome and was not classified as TRM.", [["sudden infant death syndrome", "DISEASE", 61, 89], ["patient", "ORGANISM", 8, 15], ["patient", "SPECIES", 8, 15], ["high-dose serotherapy", "TREATMENT", 29, 50], ["sudden infant death syndrome", "PROBLEM", 61, 89], ["death syndrome", "OBSERVATION", 75, 89]]], ["Cumulative survival from TRM in high-dose and low-dose serotherapy groups was 90.9% (95% confidence interval, 50.8% to 98.7%) and 100%, respectively, with no difference in survival between groups (P \u00bc .366; Figure 3) .DISCUSSIONNK and B cell reconstitution has been demonstrated to occur early after CBT, whereas low T cell numbers have been demonstrated to remain for the first 6 months post CBT [11, 30] , increasing the potential risk of viral infections as compared to BMT or PBSC [4, 5] .", [["B cell", "ANATOMY", 235, 241], ["T cell", "ANATOMY", 317, 323], ["PBSC", "ANATOMY", 480, 484], ["viral infections", "DISEASE", 441, 457], ["B cell", "CELL", 235, 241], ["T cell", "CELL", 317, 323], ["PBSC", "CELL_TYPE", 480, 484], ["Cumulative survival", "TREATMENT", 0, 19], ["TRM", "TEST", 25, 28], ["low-dose serotherapy groups", "TREATMENT", 46, 73], ["B cell reconstitution", "TREATMENT", 235, 256], ["CBT", "TEST", 300, 303], ["low T cell numbers", "PROBLEM", 313, 331], ["CBT", "TEST", 393, 396], ["viral infections", "PROBLEM", 441, 457], ["PBSC", "TEST", 480, 484], ["no", "UNCERTAINTY", 155, 157], ["viral", "OBSERVATION_MODIFIER", 441, 446], ["infections", "OBSERVATION", 447, 457]]], ["Giving T lymphocytee depleting serotherapy as GvHD prophylaxis prolongs T lymphopenia post transplantation [12, 18] and giving high doses can increase the risk of viral infection further [14, 17, [20] [21] [22] [23] [24] [25] .", [["T lymphocytee", "ANATOMY", 7, 20], ["GvHD", "DISEASE", 46, 50], ["lymphopenia", "DISEASE", 74, 85], ["viral infection", "DISEASE", 163, 178], ["T lymphocytee", "CELL", 7, 20], ["[20] [21] [22] [23] [24] [25]", "SIMPLE_CHEMICAL", 196, 225], ["T lymphocytee depleting serotherapy", "TREATMENT", 7, 42], ["GvHD prophylaxis", "TREATMENT", 46, 62], ["T lymphopenia post transplantation", "TREATMENT", 72, 106], ["viral infection", "PROBLEM", 163, 178], ["viral", "OBSERVATION_MODIFIER", 163, 168], ["infection", "OBSERVATION", 169, 178]]], ["In our study, lower dose serotherapy improved T lymphocyte reconstitution with better thymopoiesis at 4 months post transplant than high-dose serotherapy.", [["T lymphocyte", "ANATOMY", 46, 58], ["T lymphocyte", "CELL", 46, 58], ["our study", "TEST", 3, 12], ["lower dose serotherapy", "TREATMENT", 14, 36], ["T lymphocyte reconstitution", "TREATMENT", 46, 73], ["transplant", "TREATMENT", 116, 126], ["high-dose serotherapy", "TREATMENT", 132, 153], ["lymphocyte reconstitution", "OBSERVATION", 48, 73]]], ["This is particularly pertinent in the setting of CBT for PID.", [["PID", "DISEASE", 57, 60], ["PID", "PROBLEM", 57, 60]]], ["In our study, the majority of patients had SCID and, therefore, further delay in T cell reconstitution from excessive serotherapy might delay clearance of pre-existing viral infection.", [["T cell", "ANATOMY", 81, 87], ["SCID", "DISEASE", 43, 47], ["viral infection", "DISEASE", 168, 183], ["patients", "ORGANISM", 30, 38], ["T cell", "CELL", 81, 87], ["patients", "SPECIES", 30, 38], ["our study", "TEST", 3, 12], ["SCID", "PROBLEM", 43, 47], ["further delay", "PROBLEM", 64, 77], ["T cell reconstitution", "TREATMENT", 81, 102], ["excessive serotherapy", "PROBLEM", 108, 129], ["pre-existing viral infection", "PROBLEM", 155, 183], ["cell reconstitution", "OBSERVATION", 83, 102], ["viral", "OBSERVATION_MODIFIER", 168, 173], ["infection", "OBSERVATION", 174, 183]]], ["The delay in immune reconstitution between high-and lowdose serotherapy could be explained by the prolonged exposure of the graft to lympholytic antibodies when higher doses are given.", [["graft", "ANATOMY", 124, 129], ["graft", "TISSUE", 124, 129], ["lympholytic antibodies", "PROTEIN", 133, 155], ["The delay", "PROBLEM", 0, 9], ["immune reconstitution", "TREATMENT", 13, 34], ["high-and lowdose serotherapy", "TREATMENT", 43, 71], ["the graft", "TREATMENT", 120, 129], ["lympholytic antibodies", "TREATMENT", 133, 155], ["delay", "OBSERVATION_MODIFIER", 4, 9], ["immune reconstitution", "OBSERVATION", 13, 34], ["high", "OBSERVATION_MODIFIER", 43, 47], ["graft", "OBSERVATION", 124, 129]]], ["Lympholytic concentrations of alemtuzumab have been shown to be present up to 56 days after HSCT when very high doses are given in vivo [31] .DISCUSSIONA recent prospective series of 30 pediatric patients who underwent CBT for malignant and nonmalignant disease without serotherapy conditioning showed early restoration of T lymphocytes within the first 2 months post CBT from a thymic independent pathway that produced effective viral specific T cells.", [["malignant", "ANATOMY", 227, 236], ["nonmalignant disease", "ANATOMY", 241, 261], ["T lymphocytes", "ANATOMY", 323, 336], ["thymic", "ANATOMY", 379, 385], ["T cells", "ANATOMY", 445, 452], ["alemtuzumab", "CHEMICAL", 30, 41], ["malignant and nonmalignant disease", "DISEASE", 227, 261], ["alemtuzumab", "SIMPLE_CHEMICAL", 30, 41], ["patients", "ORGANISM", 196, 204], ["nonmalignant disease", "CANCER", 241, 261], ["T lymphocytes", "CELL", 323, 336], ["T cells", "CELL", 445, 452], ["T lymphocytes", "CELL_TYPE", 323, 336], ["viral specific T cells", "CELL_TYPE", 430, 452], ["patients", "SPECIES", 196, 204], ["Lympholytic concentrations", "PROBLEM", 0, 26], ["alemtuzumab", "TREATMENT", 30, 41], ["HSCT", "TREATMENT", 92, 96], ["CBT", "TEST", 219, 222], ["malignant and nonmalignant disease", "PROBLEM", 227, 261], ["serotherapy conditioning", "PROBLEM", 270, 294], ["T lymphocytes", "PROBLEM", 323, 336], ["CBT", "TEST", 368, 371], ["effective viral specific T cells", "PROBLEM", 420, 452], ["alemtuzumab", "OBSERVATION", 30, 41], ["malignant", "OBSERVATION", 227, 236], ["nonmalignant", "OBSERVATION_MODIFIER", 241, 253], ["disease", "OBSERVATION", 254, 261], ["early", "OBSERVATION_MODIFIER", 302, 307], ["restoration", "OBSERVATION_MODIFIER", 308, 319], ["T lymphocytes", "OBSERVATION", 323, 336], ["thymic", "ANATOMY", 379, 385]]], ["Thymopoiesis was evident at 1 year after transplantation [32] .", [["Thymopoiesis", "DISEASE", 0, 12], ["Thymopoiesis", "PROBLEM", 0, 12], ["transplantation", "TREATMENT", 41, 56]]], ["In contrast to this study by Chiesa et al., our study demonstrated a delayed restoration of median T cell counts until 4 months post CBT when low-dose serotherapy was given and a further delay in T lymphocyte reconstitution to 6 months post CBT when using high dose serotherapy.", [["T cell", "ANATOMY", 99, 105], ["T lymphocyte", "ANATOMY", 196, 208], ["T cell", "CELL", 99, 105], ["T lymphocyte", "CELL", 196, 208], ["this study", "TEST", 15, 25], ["our study", "TEST", 44, 53], ["median T cell counts", "TREATMENT", 92, 112], ["CBT", "TEST", 133, 136], ["low-dose serotherapy", "TREATMENT", 142, 162], ["a further delay", "PROBLEM", 177, 192], ["T lymphocyte reconstitution", "TREATMENT", 196, 223], ["CBT", "TEST", 241, 244], ["high dose serotherapy", "TREATMENT", 256, 277], ["cell counts", "OBSERVATION", 101, 112], ["lymphocyte reconstitution", "OBSERVATION", 198, 223]]], ["CD3 \u00fe reconstitution in our study improved at 4 months when low-dose serotherapy was given as compared with high-dose serotherapy, which is likely caused by corresponding improvements in CD4 \u00fe and CD4 \u00fe ETEE counts in the low-dose serotherapy group.", [["CD3", "GENE_OR_GENE_PRODUCT", 0, 3], ["CD4", "GENE_OR_GENE_PRODUCT", 187, 190], ["CD4", "GENE_OR_GENE_PRODUCT", 197, 200], ["ETEE", "GENE_OR_GENE_PRODUCT", 203, 207], ["CD3", "PROTEIN", 0, 3], ["CD4", "PROTEIN", 187, 190], ["CD4", "PROTEIN", 197, 200], ["our study", "TEST", 24, 33], ["low-dose serotherapy", "TREATMENT", 60, 80], ["high-dose serotherapy", "TREATMENT", 108, 129], ["CD4 \u00fe", "TEST", 187, 192], ["CD4", "TEST", 197, 200], ["ETEE counts", "TEST", 203, 214], ["the low-dose serotherapy group", "TREATMENT", 218, 248], ["reconstitution", "OBSERVATION", 6, 20], ["likely caused", "UNCERTAINTY", 140, 153]]], ["The evidence of thymopoiesis in the low-dose serotherapy group at 4 months again contrasts with the study by Chiesa et al. The T cell reconstitution in the low-dose serotherapy group seen in our study at 4 months post transplantation is, therefore, likely to be explained by expansion in both a thymic dependant and independent manner.DISCUSSIONPatients in our study experienced much lower rates of acute GvHD than in the study by Chiesa et al. (grade II to IV acute GvHD 25% versus 50%), though this may have been confounded by the inclusion of patients with malignant disease in the latter study [32] .", [["T cell", "ANATOMY", 127, 133], ["thymic", "ANATOMY", 295, 301], ["thymopoiesis", "DISEASE", 16, 28], ["GvHD", "DISEASE", 405, 409], ["GvHD", "DISEASE", 467, 471], ["malignant disease", "DISEASE", 560, 577], ["T cell", "CELL", 127, 133], ["patients", "ORGANISM", 546, 554], ["malignant disease", "CANCER", 560, 577], ["patients", "SPECIES", 546, 554], ["thymopoiesis", "PROBLEM", 16, 28], ["the low-dose serotherapy group", "TREATMENT", 32, 62], ["the study", "TEST", 96, 105], ["The T cell reconstitution", "TREATMENT", 123, 148], ["the low-dose serotherapy group", "TREATMENT", 152, 182], ["our study", "TEST", 191, 200], ["transplantation", "TREATMENT", 218, 233], ["our study", "TEST", 357, 366], ["acute GvHD", "PROBLEM", 399, 409], ["the study", "TEST", 418, 427], ["grade II to IV acute GvHD", "PROBLEM", 446, 471], ["malignant disease", "PROBLEM", 560, 577], ["the latter study", "TEST", 581, 597], ["evidence of", "UNCERTAINTY", 4, 15], ["thymopoiesis", "OBSERVATION", 16, 28], ["low", "OBSERVATION_MODIFIER", 36, 39], ["cell reconstitution", "OBSERVATION", 129, 148], ["low-dose", "OBSERVATION_MODIFIER", 156, 164], ["likely to be explained", "UNCERTAINTY", 249, 271], ["expansion", "OBSERVATION", 275, 284], ["thymic", "ANATOMY", 295, 301], ["dependant", "OBSERVATION", 302, 311], ["acute", "OBSERVATION_MODIFIER", 399, 404], ["GvHD", "OBSERVATION", 405, 409], ["acute", "OBSERVATION_MODIFIER", 461, 466], ["GvHD", "OBSERVATION", 467, 471], ["malignant", "OBSERVATION", 560, 569]]], ["We found the protection afforded against GvHD by lower dose serotherapy to be similar to high-dose serotherapy.", [["GvHD", "DISEASE", 41, 45], ["GvHD", "PROBLEM", 41, 45], ["lower dose serotherapy", "TREATMENT", 49, 71], ["high-dose serotherapy", "TREATMENT", 89, 110]]], ["In the study by Chiesa et al., 63% of patients had viral infections and 2 patients died from viral infection [32] .", [["viral infections", "DISEASE", 51, 67], ["viral infection", "DISEASE", 93, 108], ["patients", "ORGANISM", 38, 46], ["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 38, 46], ["patients", "SPECIES", 74, 82], ["the study", "TEST", 3, 12], ["viral infections", "PROBLEM", 51, 67], ["viral infection", "PROBLEM", 93, 108], ["infections", "OBSERVATION", 57, 67], ["viral", "OBSERVATION_MODIFIER", 93, 98], ["infection", "OBSERVATION", 99, 108]]], ["In our study, 35% of patients had pre-existing viral infection, and 35% developed new viral infection after CBT, with no difference between high-and low-dose serotherapy groups.", [["viral infection", "DISEASE", 47, 62], ["viral infection", "DISEASE", 86, 101], ["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29], ["our study", "TEST", 3, 12], ["pre-existing viral infection", "PROBLEM", 34, 62], ["new viral infection", "PROBLEM", 82, 101], ["CBT", "TEST", 108, 111], ["low-dose serotherapy groups", "TREATMENT", 149, 176], ["viral", "OBSERVATION_MODIFIER", 47, 52], ["infection", "OBSERVATION", 53, 62], ["new", "OBSERVATION_MODIFIER", 82, 85], ["viral", "OBSERVATION_MODIFIER", 86, 91], ["infection", "OBSERVATION", 92, 101], ["no", "UNCERTAINTY", 118, 120]]], ["This is important in the PID setting where many patients present with pre-existing viral illness.", [["viral illness", "DISEASE", 83, 96], ["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56], ["pre-existing viral illness", "PROBLEM", 70, 96], ["viral illness", "OBSERVATION", 83, 96]]], ["However, our definition of viral clearance and the small numbers of patients with viral infection at time of transplantation make it difficult to determine the effects of serotherapy dose on clearance of pre-existing viral infections.", [["viral infection", "DISEASE", 82, 97], ["viral infections", "DISEASE", 217, 233], ["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76], ["viral clearance", "PROBLEM", 27, 42], ["viral infection", "PROBLEM", 82, 97], ["transplantation", "TREATMENT", 109, 124], ["serotherapy dose", "TREATMENT", 171, 187], ["pre-existing viral infections", "PROBLEM", 204, 233], ["viral clearance", "OBSERVATION", 27, 42], ["small", "OBSERVATION_MODIFIER", 51, 56], ["numbers", "OBSERVATION_MODIFIER", 57, 64], ["viral", "OBSERVATION_MODIFIER", 82, 87], ["infection", "OBSERVATION", 88, 97], ["viral infections", "OBSERVATION", 217, 233]]], ["The influence of giving serotherapy on viral clearance in the context of PID and CBT needs further work with larger studies.DISCUSSIONOther single and multicenter studies of CBT for PID tended to use a standard dose of ATG as serotherapy [7] [8] [9] [10] .", [["PID", "DISEASE", 73, 76], ["PID", "DISEASE", 182, 185], ["ATG", "CHEMICAL", 219, 222], ["ATG", "SIMPLE_CHEMICAL", 219, 222], ["[7] [8] [9] [10]", "SIMPLE_CHEMICAL", 238, 254], ["serotherapy", "TREATMENT", 24, 35], ["viral clearance", "TREATMENT", 39, 54], ["PID", "PROBLEM", 73, 76], ["CBT", "TEST", 81, 84], ["larger studies", "TEST", 109, 123], ["CBT", "TEST", 174, 177], ["PID", "PROBLEM", 182, 185], ["a standard dose of ATG as serotherapy", "TREATMENT", 200, 237]]], ["Knutsen et al. demonstrated that in 8 patients with T cell immunodeficiencies who received the same dose of ATG (30 mg/kg/day for 3 days) CD4 \u00fe and CD8 \u00fe lymphocyte numbers increased from 3 months and there was evidence of thymopoiesis (using presence of CD4 \u00fe /CD45RA \u00fe cells as marker) from 12 to 24 months [9] .", [["T cell", "ANATOMY", 52, 58], ["CD8 \u00fe lymphocyte", "ANATOMY", 148, 164], ["CD4 \u00fe /CD45RA \u00fe cells", "ANATOMY", 255, 276], ["T cell immunodeficiencies", "DISEASE", 52, 77], ["ATG", "CHEMICAL", 108, 111], ["patients", "ORGANISM", 38, 46], ["T cell", "CELL", 52, 58], ["ATG", "SIMPLE_CHEMICAL", 108, 111], ["CD4", "GENE_OR_GENE_PRODUCT", 138, 141], ["CD8", "GENE_OR_GENE_PRODUCT", 148, 151], ["lymphocyte", "CELL", 154, 164], ["CD4", "GENE_OR_GENE_PRODUCT", 255, 258], ["CD45RA", "GENE_OR_GENE_PRODUCT", 262, 268], ["CD4", "PROTEIN", 138, 141], ["CD8", "PROTEIN", 148, 151], ["CD4", "PROTEIN", 255, 258], ["CD45RA", "PROTEIN", 262, 268], ["patients", "SPECIES", 38, 46], ["T cell immunodeficiencies", "PROBLEM", 52, 77], ["ATG", "TREATMENT", 108, 111], ["CD4", "TEST", 138, 141], ["CD8", "TEST", 148, 151], ["lymphocyte numbers", "TEST", 154, 172], ["thymopoiesis", "PROBLEM", 223, 235], ["CD4", "TEST", 255, 258], ["evidence of", "UNCERTAINTY", 211, 222], ["thymopoiesis", "OBSERVATION", 223, 235]]], ["This evidence of thymopoiesis occurs later than that demonstrated by the low-dose serotherapy group in our study.", [["thymopoiesis", "PROBLEM", 17, 29], ["the low-dose serotherapy group", "TREATMENT", 69, 99], ["our study", "TEST", 103, 112], ["evidence of", "UNCERTAINTY", 5, 16], ["thymopoiesis", "OBSERVATION", 17, 29]]], ["Overall other studies demonstrated higher rates of GvHD grades II to IV than our study [7] [8] [9] [10] .", [["GvHD", "DISEASE", 51, 55], ["[7] [8] [9", "SIMPLE_CHEMICAL", 87, 97], ["Overall other studies", "TEST", 0, 21], ["GvHD grades II", "PROBLEM", 51, 65], ["our study", "TEST", 77, 86]]], ["However, these rates of GvHD are more likely to be caused by the greater number of CBT with 2 or more mismatched HLA loci, as compared with our study than the difference in serotherapy used.", [["GvHD", "DISEASE", 24, 28], ["GvHD", "CANCER", 24, 28], ["HLA loci", "DNA", 113, 121], ["GvHD", "PROBLEM", 24, 28], ["more mismatched HLA loci", "PROBLEM", 97, 121], ["our study", "TEST", 140, 149], ["GvHD", "OBSERVATION", 24, 28], ["more likely to be", "UNCERTAINTY", 33, 50], ["greater", "OBSERVATION_MODIFIER", 65, 72], ["number", "OBSERVATION_MODIFIER", 73, 79], ["CBT", "OBSERVATION", 83, 86], ["mismatched", "OBSERVATION_MODIFIER", 102, 112], ["HLA loci", "OBSERVATION", 113, 121]]], ["This, combined with the use of ATG rather than alemtuzumab, makes a direct comparison to our study difficult.", [["alemtuzumab", "CHEMICAL", 47, 58], ["ATG", "SIMPLE_CHEMICAL", 31, 34], ["alemtuzumab", "SIMPLE_CHEMICAL", 47, 58], ["ATG", "TREATMENT", 31, 34], ["alemtuzumab", "TREATMENT", 47, 58], ["our study", "TEST", 89, 98]]], ["There are currently limited data regarding T cell function post CBT.", [["T cell", "ANATOMY", 43, 49], ["T cell", "CELL", 43, 49], ["CBT", "TEST", 64, 67]]], ["Proliferative responses to mitogens and viralspecific T cell function have been demonstrated as early as 2 months post CBT [9, 30, 32] .", [["viralspecific T cell", "ANATOMY", 40, 60], ["viralspecific T cell", "CELL", 40, 60], ["Proliferative responses", "PROBLEM", 0, 23], ["mitogens", "TEST", 27, 35], ["viralspecific T cell function", "TEST", 40, 69], ["CBT", "TEST", 119, 122]]], ["The T cell receptor repertoire has been shown to have a skewed distribution at 1 year post CBT but increased diversity as compared with BMT recipients at 2 years post HSCT [33] .", [["T cell", "ANATOMY", 4, 10], ["T cell receptor", "GENE_OR_GENE_PRODUCT", 4, 19], ["T cell receptor repertoire", "PROTEIN", 4, 30], ["CBT", "TEST", 91, 94], ["increased diversity", "PROBLEM", 99, 118], ["skewed", "OBSERVATION_MODIFIER", 56, 62], ["distribution", "OBSERVATION_MODIFIER", 63, 75], ["increased", "OBSERVATION_MODIFIER", 99, 108], ["diversity", "OBSERVATION_MODIFIER", 109, 118]]], ["Our current study shows that clinically there is good long-term immune function with independence from immunoglobulin replacement by 2 years post CBT and response to primary vaccinations independent of serotherapy dose.", [["immunoglobulin", "GENE_OR_GENE_PRODUCT", 103, 117], ["immunoglobulin", "PROTEIN", 103, 117], ["Our current study", "TEST", 0, 17], ["immunoglobulin replacement", "TREATMENT", 103, 129], ["CBT", "TEST", 146, 149], ["primary vaccinations", "TREATMENT", 166, 186], ["serotherapy dose", "TREATMENT", 202, 218], ["good", "OBSERVATION_MODIFIER", 49, 53], ["long-term immune", "OBSERVATION_MODIFIER", 54, 70]]], ["Our study is, however, limited to looking at numerical and not functional immune reconstitution and analysis of the effects of serotherapy on T cell functional reconstitution merits further work.DISCUSSIONOur study is limited to comparing high-and low-dose serotherapy regimens only and no comparison was made to patients not receiving serotherapy as part of their conditioning regimen.", [["T cell", "ANATOMY", 142, 148], ["T cell", "CELL", 142, 148], ["patients", "ORGANISM", 313, 321], ["patients", "SPECIES", 313, 321], ["Our study", "TEST", 0, 9], ["functional immune reconstitution", "TREATMENT", 63, 95], ["serotherapy", "TREATMENT", 127, 138], ["T cell functional reconstitution", "TREATMENT", 142, 174], ["DISCUSSIONOur study", "TEST", 195, 214], ["low-dose serotherapy regimens", "TREATMENT", 248, 277], ["serotherapy", "TREATMENT", 336, 347], ["their conditioning regimen", "TREATMENT", 359, 385], ["immune reconstitution", "OBSERVATION", 74, 95]]], ["This is because patients who did not receive serotherapy were preselected based on poor clinical condition at time of transplantation, many of whom did not receive chemotherapeutic conditioning either, or they did not receive serotherapy because they received a matched sibling donor CBT.", [["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24], ["serotherapy", "TREATMENT", 45, 56], ["poor clinical condition", "PROBLEM", 83, 106], ["transplantation", "TREATMENT", 118, 133], ["chemotherapeutic conditioning", "TREATMENT", 164, 193], ["serotherapy", "TREATMENT", 226, 237], ["a matched sibling donor CBT", "TREATMENT", 260, 287]]], ["The only factor that differed significantly between the high and low-dose serotherapy groups was that low-dose serotherapy CBT occurred more recently.", [["the high and low-dose serotherapy groups", "TREATMENT", 52, 92], ["low-dose serotherapy CBT", "TREATMENT", 102, 126]]], ["This was due to a systematic change in the serotherapy policy at our unit.", [["a systematic change", "PROBLEM", 16, 35]]], ["This would have allowed for introduction of more upto-date supportive measures in the low-dose serotherapy group, potentially influencing survival but not immune reconstitution.DISCUSSIONOur results show that low-dose serotherapy improves speed of immune reconstitution and thymopoiesis over the first year after CBT without an increase in incidence of GvHD, as compared with high dose serotherapy.", [["GvHD", "DISEASE", 353, 357], ["supportive measures", "TREATMENT", 59, 78], ["the low-dose serotherapy group", "TREATMENT", 82, 112], ["immune reconstitution", "TREATMENT", 155, 176], ["low-dose serotherapy", "TREATMENT", 209, 229], ["immune reconstitution", "TREATMENT", 248, 269], ["thymopoiesis", "PROBLEM", 274, 286], ["CBT", "TEST", 313, 316], ["GvHD", "PROBLEM", 353, 357], ["high dose serotherapy", "TREATMENT", 376, 397], ["not", "UNCERTAINTY", 151, 154], ["immune reconstitution", "OBSERVATION", 155, 176], ["immune reconstitution", "OBSERVATION", 248, 269], ["thymopoiesis", "OBSERVATION", 274, 286], ["increase", "OBSERVATION_MODIFIER", 328, 336], ["GvHD", "OBSERVATION", 353, 357]]], ["Our results also demonstrate lower rates of GvHD than in other studies.", [["GvHD", "DISEASE", 44, 48], ["lower rates of GvHD", "PROBLEM", 29, 48], ["other studies", "TEST", 57, 70], ["lower", "OBSERVATION_MODIFIER", 29, 34], ["rates", "OBSERVATION_MODIFIER", 35, 40], ["GvHD", "OBSERVATION", 44, 48]]], ["The extent that giving serotherapy affects the risk of delayed viral clearance is unclear from the current study and further research is needed.", [["delayed viral clearance", "PROBLEM", 55, 78], ["the current study", "TEST", 95, 112], ["delayed", "OBSERVATION_MODIFIER", 55, 62], ["viral clearance", "OBSERVATION", 63, 78]]]], "6e75768ec23352ae27b38c53e9569deb466c4962": [["IntroductionIn February 2020, the novel coronavirus (COVID-19) became a global pandemic, with the number of COVID-19 cases increasing dramatically in many countries (Lau et al., 2020; Wang et al., 2020) .", [["coronavirus", "ORGANISM", 40, 51], ["COVID", "TEST", 53, 58], ["a global pandemic", "PROBLEM", 70, 87], ["COVID", "TEST", 108, 113], ["global", "OBSERVATION_MODIFIER", 72, 78], ["pandemic", "OBSERVATION", 79, 87]]], ["Daily television and newspaper reports on the spread of the pandemic quickly triggered fears of an impending economic crisis and recession among the population (Nicola et al., 2020) .IntroductionAs early as February 2020, numerous reports appeared on the Internet stating that the spread of COVID-19 could endanger the supply of medicines worldwide because many drugs used globally are manufactured in China and India, where production has halted due to outbreaks of the disease.", [["COVID-19", "CHEMICAL", 291, 299], ["COVID-19", "CHEMICAL", 291, 299], ["an impending economic crisis", "PROBLEM", 96, 124], ["recession", "PROBLEM", 129, 138], ["medicines", "TREATMENT", 329, 338], ["many drugs", "TREATMENT", 357, 367], ["the disease", "PROBLEM", 467, 478], ["impending", "OBSERVATION_MODIFIER", 99, 108], ["economic crisis", "OBSERVATION", 109, 124], ["disease", "OBSERVATION", 471, 478]]], ["The German health minister feared that the COVID-19 pandemic would cause drug shortages in Europe, although there was no actual evidence that short-term supply shortages were occurring.IntroductionReports that shelf-stable foods such as flour, pasta, and canned goods were quickly selling out, leading to shortages, were published in various countries (Nicola et al., 2020) .", [["flour", "ORGANISM_SUBSTANCE", 237, 242], ["pasta", "ORGANISM_SUBDIVISION", 244, 249], ["the COVID", "TEST", 39, 48], ["short-term supply shortages", "PROBLEM", 142, 169], ["stable", "OBSERVATION_MODIFIER", 216, 222]]], ["At the same time, pharmacies reported shortages of the antipyretic paracetamol due to strong demand during the corona pandemic.IntroductionNo studies have yet been published on pharmacy sales of various drugs for the treatment of acute and chronic diseases during the pandemic.", [["paracetamol", "CHEMICAL", 67, 78], ["paracetamol", "CHEMICAL", 67, 78], ["paracetamol", "SIMPLE_CHEMICAL", 67, 78], ["the antipyretic paracetamol", "TREATMENT", 51, 78], ["strong demand", "PROBLEM", 86, 99], ["the corona pandemic", "PROBLEM", 107, 126], ["various drugs", "TREATMENT", 195, 208], ["the treatment", "TREATMENT", 213, 226], ["acute and chronic diseases", "PROBLEM", 230, 256], ["the pandemic", "PROBLEM", 264, 276], ["acute", "OBSERVATION_MODIFIER", 230, 235], ["chronic", "OBSERVATION_MODIFIER", 240, 247], ["diseases", "OBSERVATION", 248, 256]]], ["It could be assumed that people will be buying higher quantities of drugs and requesting more prescriptions if they fear extended quarantines.", [["people", "ORGANISM", 25, 31], ["people", "SPECIES", 25, 31], ["drugs", "TREATMENT", 68, 73]]], ["The aim of this study was to examine the development of drug purchases during the corona crisis.DatabaseThe evaluations in this study are based on the IMS RPM\u00ae (Regional Pharmaceutical Market) Weekly database, which shows the weekly purchases of public pharmacies from fully-stocked wholesalers at the time the pharmacy purchase is made in Germany.", [["this study", "TEST", 11, 21], ["the corona crisis", "PROBLEM", 78, 95], ["The evaluations", "TEST", 104, 119], ["this study", "TEST", 123, 133], ["drug purchases", "OBSERVATION", 56, 70], ["corona crisis", "OBSERVATION", 82, 95]]], ["Each reporting week runs from Saturday to Friday.DatabaseIn Germany, wholesalers supply pharmacies and other dispensing points with medicines and related products sold into the market by manufacturers and importers.DatabaseAll values examined are expressed in packing units, i.e. the number of packs.Study outcomeThe outcome of this investigation was the development in drug purchases by packing unit between Calendar Weeks 6 and 16.", [["medicines", "TREATMENT", 132, 141], ["DatabaseAll values", "TEST", 215, 233], ["Study outcome", "TEST", 300, 313], ["this investigation", "TEST", 328, 346], ["packing units", "OBSERVATION_MODIFIER", 260, 273]]], ["The therapeutic classes analyzed wereStatistical analysisThis study is of a descriptive nature, and no hypotheses were tested.", [["Statistical analysis", "TEST", 37, 57], ["This study", "TEST", 57, 67]]], ["Compared to Week 11, the increase in Week 12 was 43% for vitamin k antagonists, 39% for ACE inhibitors, and 37% for betablockers.DiscussionTo the best of our knowledge, this is the first study focusing on the impact of the Covid-19 pandemic on the pharmacy purchases of various drugs for the treatment of acute and chronic diseases.", [["vitamin k", "CHEMICAL", 57, 66], ["vitamin k", "CHEMICAL", 57, 66], ["vitamin k antagonists", "SIMPLE_CHEMICAL", 57, 78], ["ACE", "GENE_OR_GENE_PRODUCT", 88, 91], ["vitamin k antagonists", "TREATMENT", 57, 78], ["ACE inhibitors", "TREATMENT", 88, 102], ["betablockers", "TREATMENT", 116, 128], ["the first study", "TEST", 177, 192], ["various drugs", "TREATMENT", 270, 283], ["the treatment", "TREATMENT", 288, 301], ["acute and chronic diseases", "PROBLEM", 305, 331], ["increase", "OBSERVATION_MODIFIER", 25, 33], ["acute", "OBSERVATION_MODIFIER", 305, 310], ["chronic", "OBSERVATION_MODIFIER", 315, 322], ["diseases", "OBSERVATION", 323, 331]]], ["In our study, we have shown that pharmacy purchases were significantly higher in Calendar Week 12 than in the previous week.", [["our study", "TEST", 3, 12]]], ["Although there were differences between the various therapy classes investigated, the trends were very similar in all classes.DiscussionSocial media has played a crucial role in spreading knowledge in the field of public health.", [["the various therapy classes", "TREATMENT", 40, 67]]], ["In addition to the fear of becoming infected the virus themselves, many people prepared themselves for a possible quarantine when the virus began to spread.", [["people", "ORGANISM", 72, 78], ["people", "SPECIES", 72, 78], ["the virus themselves", "PROBLEM", 45, 65], ["the virus", "PROBLEM", 130, 139], ["infected", "OBSERVATION", 36, 44]]], ["Should a family member fall ill with the virus, the quarantine period is at least two weeks.", [["the virus", "PROBLEM", 37, 46]]], ["In severe cases, the treatment and quarantine times may be longer.", [["the treatment", "TREATMENT", 17, 30], ["quarantine times", "TREATMENT", 35, 51], ["severe", "OBSERVATION_MODIFIER", 3, 9], ["cases", "OBSERVATION", 10, 15]]], ["It is possible that people with chronic diseases tried to stock up on the medications they need for their diseases, such as cardiovascular drugs.DiscussionThe other possible reason for the increase in purchases may be a fear of drugs shortages as many drugs are produced in countries where the pandemic took hold sooner than in Germany (such as China).", [["cardiovascular", "ANATOMY", 124, 138], ["chronic diseases", "DISEASE", 32, 48], ["people", "ORGANISM", 20, 26], ["people", "SPECIES", 20, 26], ["chronic diseases", "PROBLEM", 32, 48], ["the medications", "TREATMENT", 70, 85], ["their diseases", "PROBLEM", 100, 114], ["cardiovascular drugs", "TREATMENT", 124, 144], ["chronic", "OBSERVATION_MODIFIER", 32, 39], ["diseases", "OBSERVATION", 40, 48]]], ["As a result, people tried to buy necessary medications in pharmacies while they were available.", [["people", "ORGANISM", 13, 19], ["people", "SPECIES", 13, 19], ["medications", "TREATMENT", 43, 54]]], ["Finally, there is a possibility that consumers engaged in panic buying out of a fear that all shops and pharmacies, but also private medical practices would close.DiscussionPanic buying is not a purely German phenomenon.", [["panic", "DISEASE", 58, 63], ["a purely German phenomenon", "PROBLEM", 193, 219]]], ["For example, by the middle of March, when the epidemic was spreading but nothing had been officially confirmed, signs of the panic buying of antiviral drugs had appeared in Guangdong and in Beijing (Qiu et al., 2018) .", [["panic", "DISEASE", 125, 130], ["antiviral drugs", "TREATMENT", 141, 156], ["middle", "ANATOMY_MODIFIER", 20, 26], ["antiviral drugs", "OBSERVATION", 141, 156]]], ["Similarly, reports by the media in China that extracts of forsythiae fructus dried fruit, inhibited SARS-CoV-2 in vitro, it sparked panic buying of the traditional medication both online and in stores (Liu et al., 2020) .", [["extracts", "ANATOMY", 46, 54], ["fruit", "ANATOMY", 83, 88], ["panic", "DISEASE", 132, 137], ["extracts", "ORGANISM_SUBSTANCE", 46, 54], ["forsythiae fructus", "ORGANISM", 58, 76], ["CoV-2", "ORGANISM", 105, 110], ["forsythiae fructus", "SPECIES", 58, 76], ["SARS-CoV", "SPECIES", 100, 108], ["forsythiae fructus", "PROBLEM", 58, 76], ["the traditional medication", "TREATMENT", 148, 174]]], ["Similar behaviors were observed in other countries including Japan, Australia, Italy, Spain, the UK, and the USA in March 2020 (Sim et al., 2020) .DiscussionLack of information or wrong information can lead to hysteria and panic buying (Aslani, 2020) .", [["hysteria", "DISEASE", 210, 218], ["panic", "DISEASE", 223, 228], ["hysteria", "PROBLEM", 210, 218], ["panic", "PROBLEM", 223, 228]]], ["It could also be a manifestation of the conflict between the desire to maintain regular routines and the uncertainty of how long the pandemic would last (Sim et al., 2020) .DiscussionFrom a healthcare perspective, this panic buying can have a positive effect in terms of adherence.", [["panic", "DISEASE", 219, 224]]], ["By buying medication to cover a possible quarantine period, patients avoid therapy gaps and keep taking their prescribed drugs for as long as is recommended by physicians.", [["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68], ["medication", "TREATMENT", 10, 20], ["therapy gaps", "TREATMENT", 75, 87], ["their prescribed drugs", "TREATMENT", 104, 126]]], ["Interestingly, in Germany, the significant increase in sales of long-time medications for chronic diseases occurred shortly prior to lockdown.", [["chronic diseases", "DISEASE", 90, 106], ["long-time medications", "TREATMENT", 64, 85], ["chronic diseases", "PROBLEM", 90, 106], ["significant", "OBSERVATION_MODIFIER", 31, 42], ["increase", "OBSERVATION_MODIFIER", 43, 51], ["chronic", "OBSERVATION_MODIFIER", 90, 97], ["diseases", "OBSERVATION", 98, 106]]], ["It should be noted, however that therapy for chronic disorders such as hypertension requires continuous monitoring, including blood pressure measurements.", [["blood", "ANATOMY", 126, 131], ["chronic disorders", "DISEASE", 45, 62], ["hypertension", "DISEASE", 71, 83], ["blood", "ORGANISM_SUBSTANCE", 126, 131], ["therapy", "TREATMENT", 33, 40], ["chronic disorders", "PROBLEM", 45, 62], ["hypertension", "PROBLEM", 71, 83], ["continuous monitoring", "TEST", 93, 114], ["blood pressure measurements", "TEST", 126, 153], ["hypertension", "OBSERVATION", 71, 83]]], ["Therapy must often be adapted by changing the dose, changing the medication or prescribing additional medication (Kjeldsen et al., 2014) .", [["Therapy", "TREATMENT", 0, 7], ["changing the medication", "TREATMENT", 52, 75], ["prescribing additional medication", "TREATMENT", 79, 112]]], ["This therapy monitoring can become rare when patients do not visit their physicians because they purchased sufficient medication purchased during the 'panic buying week' to last for several months.", [["panic", "DISEASE", 151, 156], ["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53], ["This therapy monitoring", "TREATMENT", 0, 23]]], ["This is why it is important to investigate the visiting behavior of patients during the next few months of the Covid-19 crisis.DiscussionThe smallest increase was observed for purchases of antidementive drugs.", [["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76], ["antidementive drugs", "TREATMENT", 189, 208], ["smallest", "OBSERVATION_MODIFIER", 141, 149], ["increase", "OBSERVATION_MODIFIER", 150, 158]]], ["There are several possible explanations for this, but there is no clear evidence supporting any of these at the present time.", [["no", "UNCERTAINTY", 63, 65]]], ["The population of dementia patients is older on average than all other populations.", [["dementia", "DISEASE", 18, 26], ["patients", "ORGANISM", 27, 35], ["patients", "SPECIES", 27, 35], ["dementia", "PROBLEM", 18, 26], ["population", "OBSERVATION_MODIFIER", 4, 14], ["dementia", "OBSERVATION", 18, 26]]], ["At the same time, this population has the highest mortality rate from Covid-19 [Leung, 2020; Zhang et al., 2020) .", [["Covid", "TEST", 70, 75]]], ["However, the majority of these patients are supported by medical professionals (nurses) or live in nursing homes (Jacob et al., 2017) .", [["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39]]], ["There are several factors impacting medication buying in this population, as several persons and institutions, often not the dementia patients themselves, may be responsible for pharmacy visits.", [["dementia", "DISEASE", 125, 133], ["persons", "ORGANISM", 85, 92], ["patients", "ORGANISM", 134, 142], ["persons", "SPECIES", 85, 92], ["patients", "SPECIES", 134, 142], ["several", "OBSERVATION_MODIFIER", 10, 17]]], ["That being said, in a study carried out in the United Kingdom, older people described themselves as being less likely to self-isolate than younger people (Bacon & Corr, 2020) .DiscussionThe findings of this secondary data analysis should be interpreted in the light of several limitations.", [["people", "ORGANISM", 69, 75], ["people", "ORGANISM", 147, 153], ["people", "SPECIES", 69, 75], ["people", "SPECIES", 147, 153], ["a study", "TEST", 20, 27], ["this secondary data analysis", "TEST", 202, 230]]], ["First, the database used does not provide information on patients, diagnoses, or prescriptions.", [["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65]]], ["It can be assumed that there is a high degree of correlation between pharmacy sell-in and sell-out data of pharmacies in Germany.", [["high degree", "OBSERVATION_MODIFIER", 34, 45]]], ["As packing units cannot be assigned to specific patients, it is not possible to stratify analyses stratified by age or sex.ConclusionsThe results of this retrospective cross-sectional study suggest that the Covid-19 lockdown in Germany was associated with a significant surge in purchasing behavior in pharmacies for different markets including psychotropic, neurological, and cardiovascular drugs.", [["cardiovascular", "ANATOMY", 377, 391], ["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56], ["packing units", "TREATMENT", 3, 16], ["this retrospective cross-sectional study", "TEST", 149, 189], ["the Covid", "TEST", 203, 212], ["psychotropic", "TREATMENT", 345, 357], ["cardiovascular drugs", "TREATMENT", 377, 397], ["not possible", "UNCERTAINTY", 64, 76], ["significant", "OBSERVATION_MODIFIER", 258, 269], ["surge", "OBSERVATION", 270, 275]]], ["Further studies are needed to investigate the sell-out data and to estimate the differences in panic buying by age and sex.Conflict of interestThe author reports no conflicts of interest in this work.FundingThis research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.", [["panic", "DISEASE", 95, 100], ["Further studies", "TEST", 0, 15], ["no", "UNCERTAINTY", 162, 164]]]], "a0bc6bc5b8547b98a2d77b81ca81cb18fa1b7ee9": [["To the editor, We read with great interest the correspondence by Dr. Raony Considering these contradictory data, further research on COVID-19 retinal outcomes is warranted.", [["retinal", "ANATOMY", 142, 149], ["retinal", "MULTI-TISSUE_STRUCTURE", 142, 149], ["COVID", "TEST", 133, 138]]], ["Whether SARS-CoV-2 infection may precipitate or exacerbate retinal lesions in patients with DM in the short-or long-term requires to be carefully evaluated.Key wordsCOVID-19, SARS-Cov-2, CD147, Diabetes, RetinaFundingNo funding has been received for the preparation of this manuscript.Declaration of Competing InterestThe authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.", [["retinal lesions", "ANATOMY", 59, 74], ["infection", "DISEASE", 19, 28], ["retinal lesions", "DISEASE", 59, 74], ["DM", "DISEASE", 92, 94], ["Diabetes", "DISEASE", 194, 202], ["SARS-CoV-2", "ORGANISM", 8, 18], ["retinal lesions", "PATHOLOGICAL_FORMATION", 59, 74], ["patients", "ORGANISM", 78, 86], ["CD147", "GENE_OR_GENE_PRODUCT", 187, 192], ["CD147", "PROTEIN", 187, 192], ["patients", "SPECIES", 78, 86], ["SARS-CoV", "SPECIES", 8, 16], ["SARS", "PROBLEM", 8, 12], ["CoV-2 infection", "PROBLEM", 13, 28], ["retinal lesions", "PROBLEM", 59, 74], ["DM", "PROBLEM", 92, 94], ["Key wordsCOVID", "TEST", 156, 170], ["SARS", "TEST", 175, 179], ["Cov", "TEST", 180, 183], ["Diabetes", "PROBLEM", 194, 202], ["retinal", "ANATOMY", 59, 66], ["lesions", "OBSERVATION", 67, 74], ["Diabetes", "OBSERVATION", 194, 202], ["funding", "OBSERVATION", 220, 227]]]], "PMC7524530": [["IntroductionNearly nine months have passed since the first mention of SARS-CoV-2, initially described as a mysterious respiratory illness [1] that has gone on to catch the world off-guard.", [["respiratory", "ANATOMY", 118, 129], ["SARS", "DISEASE", 70, 74], ["respiratory illness", "DISEASE", 118, 137], ["SARS-CoV", "SPECIES", 70, 78], ["SARS", "PROBLEM", 70, 74], ["a mysterious respiratory illness", "PROBLEM", 105, 137]]], ["Since then we have learned a great deal about COVID-19 and made important strides in patient care including pivoting away from preemptive intubation, which may have inflated early mortality [2].", [["patient", "ORGANISM", 85, 92], ["patient", "SPECIES", 85, 92], ["preemptive intubation", "TREATMENT", 127, 148]]], ["Since the outset, a severe phenotype of the disease associated with elevated markers of inflammation and culminating in substantial lung injury and death has been recognized to develop in a subset of patients [3].", [["lung", "ANATOMY", 132, 136], ["inflammation", "DISEASE", 88, 100], ["lung injury", "DISEASE", 132, 143], ["death", "DISEASE", 148, 153], ["lung", "ORGAN", 132, 136], ["patients", "ORGANISM", 200, 208], ["patients", "SPECIES", 200, 208], ["a severe phenotype of the disease", "PROBLEM", 18, 51], ["elevated markers of inflammation", "PROBLEM", 68, 100], ["substantial lung injury", "PROBLEM", 120, 143], ["death", "PROBLEM", 148, 153], ["severe", "OBSERVATION_MODIFIER", 20, 26], ["phenotype", "OBSERVATION", 27, 36], ["disease", "OBSERVATION", 44, 51], ["elevated", "OBSERVATION_MODIFIER", 68, 76], ["markers", "OBSERVATION_MODIFIER", 77, 84], ["inflammation", "OBSERVATION", 88, 100], ["substantial", "OBSERVATION_MODIFIER", 120, 131], ["lung", "ANATOMY", 132, 136], ["injury", "OBSERVATION", 137, 143]]], ["Studies of potential treatments aimed at prevention and treatment of this phenotype have focused on medications with antiviral, antithrombotic, and/or anti-inflammatory properties.", [["potential treatments", "TREATMENT", 11, 31], ["treatment", "TREATMENT", 56, 65], ["this phenotype", "PROBLEM", 69, 83], ["medications", "TREATMENT", 100, 111], ["antiviral", "TREATMENT", 117, 126], ["antithrombotic", "TREATMENT", 128, 142], ["anti-inflammatory properties", "TREATMENT", 151, 179]]], ["One of these treatments, dexamethasone, has already demonstrated a mortality benefit in a large randomized controlled trial [4].", [["dexamethasone", "CHEMICAL", 25, 38], ["dexamethasone", "CHEMICAL", 25, 38], ["dexamethasone", "SIMPLE_CHEMICAL", 25, 38], ["these treatments", "TREATMENT", 7, 23], ["dexamethasone", "TREATMENT", 25, 38], ["a large randomized controlled trial", "TREATMENT", 88, 123]]], ["Analogies with cytokine storm, which may or may not be an apt comparison [5], have led to an interest in IL-6 inhibition as a therapeutic modality for severe COVID-19.", [["COVID-19", "CHEMICAL", 158, 166], ["IL-6", "GENE_OR_GENE_PRODUCT", 105, 109], ["cytokine", "PROTEIN", 15, 23], ["IL-6", "PROTEIN", 105, 109], ["severe COVID", "PROBLEM", 151, 163]]], ["Tocilizumab is a biological IL-6 inhibitor therapy that is used for the treatment of rheumatoid arthritis and giant cell arteritis.", [["giant cell", "ANATOMY", 110, 120], ["Tocilizumab", "CHEMICAL", 0, 11], ["rheumatoid arthritis", "DISEASE", 85, 105], ["giant cell arteritis", "DISEASE", 110, 130], ["Tocilizumab", "CHEMICAL", 0, 11], ["Tocilizumab", "SIMPLE_CHEMICAL", 0, 11], ["IL-6", "GENE_OR_GENE_PRODUCT", 28, 32], ["giant cell", "CELL", 110, 120], ["Tocilizumab", "TREATMENT", 0, 11], ["a biological IL-6 inhibitor therapy", "TREATMENT", 15, 50], ["rheumatoid arthritis", "PROBLEM", 85, 105], ["giant cell arteritis", "PROBLEM", 110, 130], ["rheumatoid arthritis", "OBSERVATION", 85, 105], ["giant cell arteritis", "OBSERVATION", 110, 130]]], ["Indeed, several observational cohorts have explored the repurposing of tocilizumab for COVID-19 [6] [Also Cite Martinez-Sanz et al., CMI when in press] and there are, at present, dozens of registered clinical trials involving tocilizumab or sarilumab.IntroductionAgainst this backdrop, in a recent issue of Clinical Microbiology and Infection, Rodr\u00edguez-Ba\u00f1o et. al [7] tackle the management of patients with an inflammatory presentation by providing observational data in support of tocilizumab for select patients with COVID-19.", [["tocilizumab", "CHEMICAL", 71, 82], ["tocilizumab", "CHEMICAL", 226, 237], ["sarilumab", "CHEMICAL", 241, 250], ["Infection", "DISEASE", 333, 342], ["COVID-19", "CHEMICAL", 87, 95], ["sarilumab", "CHEMICAL", 241, 250], ["tocilizumab", "SIMPLE_CHEMICAL", 71, 82], ["tocilizumab", "SIMPLE_CHEMICAL", 226, 237], ["sarilumab", "SIMPLE_CHEMICAL", 241, 250], ["patients", "ORGANISM", 395, 403], ["tocilizumab", "SIMPLE_CHEMICAL", 484, 495], ["patients", "ORGANISM", 507, 515], ["patients", "SPECIES", 395, 403], ["patients", "SPECIES", 507, 515], ["tocilizumab", "TREATMENT", 71, 82], ["COVID", "TEST", 87, 92], ["tocilizumab", "TREATMENT", 226, 237], ["sarilumab", "TREATMENT", 241, 250], ["Clinical Microbiology", "TEST", 307, 328], ["Infection", "PROBLEM", 333, 342], ["Rodr\u00edguez", "TEST", 344, 353], ["the management", "TREATMENT", 377, 391], ["an inflammatory presentation", "PROBLEM", 409, 437], ["tocilizumab", "TREATMENT", 484, 495], ["COVID", "TEST", 521, 526], ["Infection", "OBSERVATION", 333, 342], ["inflammatory", "OBSERVATION", 412, 424]]], ["The authors conducted a retrospective cohort study in patients admitted to sixty hospitals in Spain between February 2 and March 31, 2020.", [["patients", "ORGANISM", 54, 62], ["patients", "SPECIES", 54, 62], ["a retrospective cohort study", "TEST", 22, 50]]], ["Patients selected for inclusion in this analysis were clinically ill with both fever and oxygen requirements at study enrollment but without immediate need for mechanical ventilation.", [["fever", "DISEASE", 79, 84], ["oxygen", "CHEMICAL", 89, 95], ["oxygen", "CHEMICAL", 89, 95], ["Patients", "ORGANISM", 0, 8], ["oxygen", "SIMPLE_CHEMICAL", 89, 95], ["Patients", "SPECIES", 0, 8], ["this analysis", "TEST", 35, 48], ["both fever", "PROBLEM", 74, 84], ["oxygen requirements", "PROBLEM", 89, 108], ["mechanical ventilation", "TREATMENT", 160, 182], ["fever", "OBSERVATION", 79, 84], ["oxygen requirements", "OBSERVATION", 89, 108], ["mechanical ventilation", "OBSERVATION", 160, 182]]], ["Most importantly, they selected patients with signs of a \u201chyperinflammatory\u201d response, which the authors defined by presence of an elevation in ferritin, D-dimer, and/or IL-6 levels.", [["patients", "ORGANISM", 32, 40], ["ferritin", "GENE_OR_GENE_PRODUCT", 144, 152], ["D-dimer", "GENE_OR_GENE_PRODUCT", 154, 161], ["IL-6", "GENE_OR_GENE_PRODUCT", 170, 174], ["ferritin", "PROTEIN", 144, 152], ["patients", "SPECIES", 32, 40], ["a \u201chyperinflammatory\u201d response", "PROBLEM", 55, 85], ["an elevation in ferritin", "PROBLEM", 128, 152], ["D-dimer", "TEST", 154, 161], ["IL", "TEST", 170, 172], ["elevation", "OBSERVATION", 131, 140]]], ["After adjustment for several potential confounders, using a variety of techniques, the authors found that the receipt of tocilizumab without corticosteroids was associated with reduced hazard for intubation or death.", [["tocilizumab", "CHEMICAL", 121, 132], ["corticosteroids", "CHEMICAL", 141, 156], ["death", "DISEASE", 210, 215], ["corticosteroids", "CHEMICAL", 141, 156], ["tocilizumab", "SIMPLE_CHEMICAL", 121, 132], ["a variety of techniques", "TREATMENT", 58, 81], ["tocilizumab", "TREATMENT", 121, 132], ["corticosteroids", "TREATMENT", 141, 156], ["intubation", "TREATMENT", 196, 206], ["death", "PROBLEM", 210, 215]]], ["By contrast, neither steroid therapy alone nor in combination with tocilizumab was convincingly protective for either outcome.", [["steroid", "CHEMICAL", 21, 28], ["tocilizumab", "CHEMICAL", 67, 78], ["steroid", "CHEMICAL", 21, 28], ["steroid", "SIMPLE_CHEMICAL", 21, 28], ["tocilizumab", "SIMPLE_CHEMICAL", 67, 78], ["neither steroid therapy", "TREATMENT", 13, 36], ["tocilizumab", "TREATMENT", 67, 78]]], ["Of note, a second observational study from Spain [Cite Martinez-Sanz et al. when it is in press] was subsequently published in Clinical Microbiology and Infection and reported a decreased risk of death when tocilizumab was given to patients with high levels of C-reactive protein (>150mg/L).Strengths and weaknessesRodriguez-Ba\u00f1o et al appropriately adjusted for several comorbidities and used propensity score methods.", [["Infection", "DISEASE", 153, 162], ["death", "DISEASE", 196, 201], ["tocilizumab", "CHEMICAL", 207, 218], ["tocilizumab", "SIMPLE_CHEMICAL", 207, 218], ["patients", "ORGANISM", 232, 240], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 261, 279], ["C-reactive protein", "PROTEIN", 261, 279], ["patients", "SPECIES", 232, 240], ["a second observational study", "TEST", 9, 37], ["Infection", "PROBLEM", 153, 162], ["death", "PROBLEM", 196, 201], ["tocilizumab", "TREATMENT", 207, 218], ["high levels of C-reactive protein", "PROBLEM", 246, 279], ["several comorbidities", "PROBLEM", 363, 384], ["Infection", "OBSERVATION", 153, 162]]], ["Prior to propensity score matching, the treatment groups differed, with a higher prevalence of cardiac disease and severe renal insufficiency in the untreated group.", [["cardiac", "ANATOMY", 95, 102], ["renal", "ANATOMY", 122, 127], ["cardiac disease", "DISEASE", 95, 110], ["renal insufficiency", "DISEASE", 122, 141], ["cardiac", "ORGAN", 95, 102], ["renal", "ORGAN", 122, 127], ["the treatment groups", "TREATMENT", 36, 56], ["cardiac disease", "PROBLEM", 95, 110], ["severe renal insufficiency", "PROBLEM", 115, 141], ["cardiac", "ANATOMY", 95, 102], ["disease", "OBSERVATION", 103, 110], ["severe", "OBSERVATION_MODIFIER", 115, 121], ["renal", "ANATOMY", 122, 127], ["insufficiency", "OBSERVATION", 128, 141]]], ["Comparatively, the tocilizumab group also had a longer median duration of illness and hospitalization prior to enrolment as well as lower adverse negative prognostic markers (ferritin and D-dimer).", [["illness", "DISEASE", 74, 81], ["ferritin", "GENE_OR_GENE_PRODUCT", 175, 183], ["D-dimer", "GENE_OR_GENE_PRODUCT", 188, 195], ["ferritin", "PROTEIN", 175, 183], ["D-dimer", "PROTEIN", 188, 195], ["enrolment", "TREATMENT", 111, 120], ["lower adverse negative prognostic markers", "PROBLEM", 132, 173], ["ferritin", "TEST", 175, 183]]], ["Even after propensity score matching, some of these imbalances persisted.", [["imbalances", "OBSERVATION", 52, 62]]], ["The major challenge due to the study design is that we will never know with certainty why in some cases a given therapy was chosen over no therapy at all.", [["the study", "TEST", 27, 36], ["therapy", "TREATMENT", 112, 119], ["therapy", "TREATMENT", 139, 146]]], ["Likewise, it is hard to ascertain through observational data alone whether patients who received tocilizumab monotherapy were systematically treated differently than those who did not.Strengths and weaknessesAdditionally, the authors attempted to address immortal time bias by excluding early primary outcomes and performing a sensitivity analysis with a time dependent covariate.", [["tocilizumab", "CHEMICAL", 97, 108], ["patients", "ORGANISM", 75, 83], ["tocilizumab", "SIMPLE_CHEMICAL", 97, 108], ["patients", "SPECIES", 75, 83], ["tocilizumab monotherapy", "TREATMENT", 97, 120], ["a sensitivity analysis", "TEST", 325, 347], ["a time dependent covariate", "TREATMENT", 353, 379]]], ["Yet, there is likely residual survivor bias as the fundamental definition of day 0 did not correspond to the day of admission, rather to the time of enrollment in the cohort.", [["residual survivor bias", "PROBLEM", 21, 43], ["likely", "UNCERTAINTY", 14, 20], ["residual", "OBSERVATION_MODIFIER", 21, 29], ["survivor bias", "OBSERVATION", 30, 43]]], ["As such, the tocilizumab group was further along in the illness trajectory with a median of 10 days of symptoms (IQR 8-13) vs. 8 days for the untreated group (IQR 6-11) and a median of 3 days in hospital (IQR 1-5) as compared to 1 (IQR 0-4) for the untreated group.", [["illness", "DISEASE", 56, 63], ["tocilizumab", "SIMPLE_CHEMICAL", 13, 24], ["the tocilizumab group", "TREATMENT", 9, 30], ["symptoms", "PROBLEM", 103, 111]]], ["Both factors may have had a bearing on the likelihood of death over the subsequent 21 days.Context with data from Randomized Controlled TrialsOne of the unexpected findings from this study was an observed lack of benefit from steroids in contrast to the RECOVERY randomized controlled trial results[4] or a recent meta-analysis of steroid trials in critically ill patients.[9] There are several ways this can be reconciled.", [["death", "DISEASE", 57, 62], ["steroids", "CHEMICAL", 226, 234], ["steroid", "CHEMICAL", 331, 338], ["critically ill", "DISEASE", 349, 363], ["steroids", "CHEMICAL", 226, 234], ["steroid", "CHEMICAL", 331, 338], ["steroids", "SIMPLE_CHEMICAL", 226, 234], ["patients", "ORGANISM", 364, 372], ["patients", "SPECIES", 364, 372], ["death", "PROBLEM", 57, 62], ["this study", "TEST", 178, 188], ["steroids", "TREATMENT", 226, 234], ["steroid trials", "TREATMENT", 331, 345]]], ["Perhaps like in the tale of \u201cGoldilocks\u201d, the \u201cporridge was too hot\u201d: many patients received 10x the dose of steroids used in the RECOVERY trial and less than 10% of the cohort was treated with dexamethasone.", [["steroids", "CHEMICAL", 109, 117], ["dexamethasone", "CHEMICAL", 194, 207], ["steroids", "CHEMICAL", 109, 117], ["dexamethasone", "CHEMICAL", 194, 207], ["patients", "ORGANISM", 75, 83], ["dexamethasone", "SIMPLE_CHEMICAL", 194, 207], ["patients", "SPECIES", 75, 83], ["steroids", "TREATMENT", 109, 117], ["dexamethasone", "TREATMENT", 194, 207]]], ["While it is tantalizing to assume that the steroid effect is a class effect, dexamethasone may work differently with its lack of mineralocorticoid activity and longer half-life.", [["steroid", "CHEMICAL", 43, 50], ["dexamethasone", "CHEMICAL", 77, 90], ["steroid", "CHEMICAL", 43, 50], ["dexamethasone", "CHEMICAL", 77, 90], ["steroid", "SIMPLE_CHEMICAL", 43, 50], ["dexamethasone", "SIMPLE_CHEMICAL", 77, 90], ["mineralocorticoid", "SIMPLE_CHEMICAL", 129, 146], ["the steroid effect", "PROBLEM", 39, 57], ["dexamethasone", "TREATMENT", 77, 90], ["mineralocorticoid activity", "PROBLEM", 129, 155]]], ["Indeed, a recent randomized controlled trial of methylprednisolone at higher equivalent doses to RECOVERY\u2019s dexamethasone failed to demonstrate a mortality benefit[10] and methylprednisolone appeared to have the least benefit in the meta-analysis [9].", [["methylprednisolone", "CHEMICAL", 48, 66], ["dexamethasone", "CHEMICAL", 108, 121], ["methylprednisolone", "CHEMICAL", 172, 190], ["methylprednisolone", "CHEMICAL", 48, 66], ["dexamethasone", "CHEMICAL", 108, 121], ["methylprednisolone", "CHEMICAL", 172, 190], ["methylprednisolone", "SIMPLE_CHEMICAL", 48, 66], ["dexamethasone", "SIMPLE_CHEMICAL", 108, 121], ["methylprednisolone", "SIMPLE_CHEMICAL", 172, 190], ["methylprednisolone", "TREATMENT", 48, 66], ["dexamethasone", "TREATMENT", 108, 121], ["methylprednisolone", "TREATMENT", 172, 190]]], ["Finally, the patients in the SAM-COVID-19 cohort differed from those in RECOVERY with a lower prevalence of heart and kidney disease and fewer mechanically ventilated patients (1-3% vs. 15%) who seem to benefit most from steroids.", [["heart", "ANATOMY", 108, 113], ["kidney", "ANATOMY", 118, 124], ["heart and kidney disease", "DISEASE", 108, 132], ["steroids", "CHEMICAL", 221, 229], ["steroids", "CHEMICAL", 221, 229], ["patients", "ORGANISM", 13, 21], ["heart", "ORGAN", 108, 113], ["kidney", "ORGAN", 118, 124], ["patients", "ORGANISM", 167, 175], ["steroids", "SIMPLE_CHEMICAL", 221, 229], ["patients", "SPECIES", 13, 21], ["patients", "SPECIES", 167, 175], ["heart and kidney disease", "PROBLEM", 108, 132], ["fewer mechanically ventilated patients", "PROBLEM", 137, 175], ["steroids", "TREATMENT", 221, 229], ["heart", "ANATOMY", 108, 113], ["kidney", "ANATOMY", 118, 124], ["disease", "OBSERVATION", 125, 132], ["fewer", "OBSERVATION_MODIFIER", 137, 142], ["mechanically", "OBSERVATION_MODIFIER", 143, 155], ["ventilated", "OBSERVATION", 156, 166]]], ["Finally, we must always consider the possibility of residual confounding by indication and/or other differences in the care received by the steroid group in the present trial.Context with data from Randomized Controlled TrialsIt is also important to put this observational data in context with several industry-sponsored trials that have examined IL-6 inhibiting monoclonal antibodies with disappointing conclusions.", [["steroid", "CHEMICAL", 140, 147], ["steroid", "CHEMICAL", 140, 147], ["steroid", "SIMPLE_CHEMICAL", 140, 147], ["IL-6", "GENE_OR_GENE_PRODUCT", 347, 351], ["IL-6", "PROTEIN", 347, 351], ["monoclonal antibodies", "PROTEIN", 363, 384], ["the steroid group", "TREATMENT", 136, 153], ["Randomized Controlled Trials", "TREATMENT", 198, 226], ["IL", "TEST", 347, 349], ["monoclonal antibodies", "TREATMENT", 363, 384]]], ["The phase III COVACTA trial (NCT04317092) found tocilizumab did not reduce mortality in hospitalized patients with severe COVID-19 pneumonia[11].", [["tocilizumab", "CHEMICAL", 48, 59], ["COVID", "DISEASE", 122, 127], ["pneumonia", "DISEASE", 131, 140], ["tocilizumab", "SIMPLE_CHEMICAL", 48, 59], ["patients", "ORGANISM", 101, 109], ["patients", "SPECIES", 101, 109], ["The phase III COVACTA trial", "TREATMENT", 0, 27], ["tocilizumab", "TREATMENT", 48, 59], ["severe COVID", "PROBLEM", 115, 127], ["pneumonia", "PROBLEM", 131, 140], ["pneumonia", "OBSERVATION", 131, 140]]], ["Similarly a large trial of sarilumab (NCT04315298) in severe and critical COVID-19 was stopped by the data safety monitoring board due to lack of benefit and a potential signal for harm in non-ventilated patients[12] and a second international trial (NCT04327388) also failed to meet its primary or key secondary outcomes[13].", [["sarilumab", "CHEMICAL", 27, 36], ["sarilumab", "CHEMICAL", 27, 36], ["NCT04315298", "CHEMICAL", 38, 49], ["sarilumab", "SIMPLE_CHEMICAL", 27, 36], ["patients", "ORGANISM", 204, 212], ["patients", "SPECIES", 204, 212], ["sarilumab", "TREATMENT", 27, 36], ["large", "OBSERVATION_MODIFIER", 12, 17], ["severe", "OBSERVATION_MODIFIER", 54, 60]]], ["Whether or not a specific subgroup of patients with a hyperinflammatory response might benefit as proposed by the authors remains to be seen in future (ideally randomized) trials.ImplicationsEarly rapid mobilization of research efforts allowed the investigators to collect valuable data through an observational cohort study and important attempts were made to control for confounding by indication and survivor bias in the analyses.", [["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46], ["a hyperinflammatory response", "PROBLEM", 52, 80], ["an observational cohort study", "TEST", 295, 324]]], ["The authors appropriately conclude with a proposal to investigate the role of IL-6 inhibition as dexamethasone emerges as standard of care, and they caution against widespread use based on observational data alone.", [["dexamethasone", "CHEMICAL", 97, 110], ["dexamethasone", "CHEMICAL", 97, 110], ["IL-6", "GENE_OR_GENE_PRODUCT", 78, 82], ["dexamethasone", "SIMPLE_CHEMICAL", 97, 110], ["IL-6", "PROTEIN", 78, 82], ["IL-6 inhibition", "TREATMENT", 78, 93], ["dexamethasone", "TREATMENT", 97, 110], ["observational data", "TEST", 189, 207]]], ["Reconciling their results with those from randomized control trials raises important questions about the causal effect of the hyperinflammatory response and its role in the development of severe COVID-19.", [["COVID", "DISEASE", 195, 200], ["COVID-19", "CHEMICAL", 195, 203], ["randomized control trials", "TREATMENT", 42, 67], ["the hyperinflammatory response", "PROBLEM", 122, 152], ["severe COVID", "PROBLEM", 188, 200], ["severe", "OBSERVATION_MODIFIER", 188, 194]]], ["Given the promising findings associated with the use of corticosteroids, we speculate whether a broader anti-inflammatory approach is the best option for most patients, whereas only a subset of patients might benefit from targeted anti-inflammatory management.", [["corticosteroids", "CHEMICAL", 56, 71], ["patients", "ORGANISM", 159, 167], ["patients", "ORGANISM", 194, 202], ["patients", "SPECIES", 159, 167], ["patients", "SPECIES", 194, 202], ["corticosteroids", "TREATMENT", 56, 71], ["a broader anti-inflammatory approach", "TREATMENT", 94, 130], ["targeted anti-inflammatory management", "TREATMENT", 222, 259], ["anti-inflammatory", "OBSERVATION_MODIFIER", 231, 248]]], ["We hope that trials like RECOVERY (www.recoverytrial.net) and REMAP-CAP (www.remapcap.org) will soon bring substantial clarity to the role, if any, that drugs like tocilizumab might play in combating the worldwide COVID-19 tempest.CRediT StatementConceptualization: TCL and EGM; writing \u2013 original draft: TCL and EGM; writing \u2013 review & editing: all authors.", [["tocilizumab", "CHEMICAL", 164, 175], ["tocilizumab", "SIMPLE_CHEMICAL", 164, 175], ["drugs", "TREATMENT", 153, 158], ["tocilizumab", "TREATMENT", 164, 175]]]], "15ca6a886738313ed672a9977f39accde4b62d60": [["A long-term developmentNosology expansion occurs either by (1) adding newly occurring diseases with distinctive characteristics (e.g. emerging infectious disease like Zika Virus Infections or the Coronaviruses and Acute Respiratory Syndromes) [2] or (2) splitting an existing disease into finer categories (in fashionable language, into \"finer granularity\") or (3) annexing to a known disease some manifestations, including precursors, previously unknown or known but regarded as outside the disease boundaries.", [["infectious disease", "DISEASE", 143, 161], ["Zika Virus Infections", "DISEASE", 167, 188], ["Respiratory Syndromes", "DISEASE", 220, 241], ["Zika Virus", "ORGANISM", 167, 177], ["A long-term developmentNosology expansion", "PROBLEM", 0, 41], ["newly occurring diseases", "PROBLEM", 70, 94], ["distinctive characteristics", "PROBLEM", 100, 127], ["emerging infectious disease", "PROBLEM", 134, 161], ["Zika Virus Infections", "PROBLEM", 167, 188], ["the Coronaviruses", "PROBLEM", 192, 209], ["Acute Respiratory Syndromes)", "PROBLEM", 214, 242], ["an existing disease into finer categories", "PROBLEM", 264, 305], ["a known disease some manifestations", "PROBLEM", 377, 412], ["long-term", "OBSERVATION_MODIFIER", 2, 11], ["diseases", "OBSERVATION", 86, 94], ["Acute", "OBSERVATION_MODIFIER", 214, 219], ["Respiratory Syndromes", "OBSERVATION", 220, 241], ["disease", "OBSERVATION", 276, 283], ["disease", "OBSERVATION", 492, 499]]], ["A related, strictly speaking different but practically important expansion occurs when cut-off levels of a disease risk factor are changed.A long-term developmentThese processes are inherent in the expansion of knowledge and of diagnostic tools brought about by scientific and technological research over centuries, especially the last two.", [["a disease risk factor", "PROBLEM", 105, 126], ["A long-term development", "PROBLEM", 139, 162], ["expansion", "OBSERVATION_MODIFIER", 65, 74], ["long-term development", "OBSERVATION_MODIFIER", 141, 162], ["expansion", "OBSERVATION_MODIFIER", 198, 207]]], ["Diseases are not only multiplied but some of them may in turn be regrouped (lumped) in new ways, the net result being however an uninterrupted secular increase in the number of distinct entities that since 1900 are included in the successive revisions of the international reference nosology, entrusted from 1948 to the World Health Organization and currently labelled \"International Classification of Diseases and Related Health Problems (ICD)\" [3] .A long-term developmentThe system is based on existing knowledge and-at the same time-tailored for multiple uses in clinical medicine, public health and research.", [["Diseases", "PROBLEM", 0, 8], ["an uninterrupted secular increase", "PROBLEM", 126, 159], ["Diseases", "PROBLEM", 402, 410], ["A long-term development", "PROBLEM", 451, 474], ["secular", "OBSERVATION_MODIFIER", 143, 150], ["increase", "OBSERVATION_MODIFIER", 151, 159], ["long-term development", "OBSERVATION_MODIFIER", 453, 474]]], ["The periodical reclassifications involve both changes in disease category definition and in the rules to assign disease cases to categories, with consequent unavoidable complexity, appreciable by even a cursory look at the freshly published documentation on the latest ICD revision (number 11, scheduled for general use on 1 January 2022).A long-term developmentTo the epidemiologist reclassification opens the field for descriptive and analytical studies of newly defined diseases but also generates familiar comparability problems.", [["both changes in disease category definition", "PROBLEM", 41, 84], ["consequent unavoidable complexity", "PROBLEM", 146, 179], ["the latest ICD revision", "TREATMENT", 258, 281], ["A long-term development", "PROBLEM", 339, 362], ["analytical studies", "TEST", 437, 455], ["newly defined diseases", "PROBLEM", 459, 481], ["both", "OBSERVATION_MODIFIER", 41, 45], ["long-term development", "OBSERVATION_MODIFIER", 341, 362]]], ["In actual practice not all countries introduce a new ICD revision at the same time: as a consequence in international studies endpoints such as causes of deaths need to be classified, for the sake of comparability, by the oldest ICD version in use among participating countries, underusing the more detailed and updated information available from countries employing more recent ICD versions.", [["deaths", "DISEASE", 154, 160], ["a new ICD revision", "TREATMENT", 47, 65], ["ICD", "OBSERVATION", 229, 232]]], ["For instance pleural mesothelioma, a critical endpoint in occupational or environmental studies on asbestos and mineral fibers, was not precisely identified as such until the tenth ICD revision (1990) [3] .", [["pleural mesothelioma", "ANATOMY", 13, 33], ["mineral fibers", "ANATOMY", 112, 126], ["pleural mesothelioma", "DISEASE", 13, 33], ["asbestos", "CHEMICAL", 99, 107], ["pleural mesothelioma", "CANCER", 13, 33], ["asbestos", "SIMPLE_CHEMICAL", 99, 107], ["instance pleural mesothelioma", "PROBLEM", 4, 33], ["environmental studies", "TEST", 74, 95], ["asbestos and mineral fibers", "TREATMENT", 99, 126], ["the tenth ICD revision", "TREATMENT", 171, 193], ["pleural", "ANATOMY", 13, 20], ["mesothelioma", "OBSERVATION", 21, 33]]], ["Mostly affected by reclassification is the interpretation of long-term time trends of diseases incidence and mortality.", [["diseases incidence", "PROBLEM", 86, 104]]], ["A by now classic example [4] is the delayed recognition, met with surprise, of the downturn in the ischemic heart disease mortality occurring in the USA in the 1960s.", [["heart", "ANATOMY", 108, 113], ["ischemic heart disease", "DISEASE", 99, 121], ["heart", "ORGAN", 108, 113], ["the delayed recognition", "PROBLEM", 32, 55], ["the ischemic heart disease mortality", "PROBLEM", 95, 131], ["ischemic", "OBSERVATION_MODIFIER", 99, 107], ["heart", "ANATOMY", 108, 113], ["disease", "OBSERVATION", 114, 121]]], ["An obscuring effect had been introduced by the change from the seventh to the new (eight) ICD revision, deaths previously and separately assigned to arteriosclerotic heart disease by the seventh revision being merged into the ischemic heart disease category by the eight.A long-term developmentOfficial inclusion of a disease in an ICD revision as a distinct entity is necessarily preceded by a phase, sometimes long, of recognition in medical practice according to criteria proposed by experts and today usually recommended in Rodolfo Saracci-Former President of International Epidemiological Association.A long-term development* Rodolfo Saracci saracci@hotmail.com 1 7 rue Saint Hippolyte, 69008 Lyon, France guidelines by scientific societies or \"ad hoc\" expert groups.", [["heart", "ANATOMY", 166, 171], ["heart", "ANATOMY", 235, 240], ["deaths", "DISEASE", 104, 110], ["arteriosclerotic heart disease", "DISEASE", 149, 179], ["ischemic heart disease", "DISEASE", 226, 248], ["heart", "ORGAN", 166, 171], ["heart", "ORGAN", 235, 240], ["ICD revision", "TREATMENT", 90, 102], ["arteriosclerotic heart disease", "PROBLEM", 149, 179], ["the seventh revision", "TREATMENT", 183, 203], ["the ischemic heart disease category", "PROBLEM", 222, 257], ["A long-term development", "PROBLEM", 271, 294], ["a disease", "PROBLEM", 316, 325], ["an ICD revision", "TREATMENT", 329, 344], ["obscuring", "OBSERVATION_MODIFIER", 3, 12], ["effect", "OBSERVATION", 13, 19], ["revision", "OBSERVATION", 94, 102], ["arteriosclerotic", "OBSERVATION_MODIFIER", 149, 165], ["heart", "ANATOMY", 166, 171], ["disease", "OBSERVATION", 172, 179], ["revision", "OBSERVATION", 195, 203], ["ischemic", "OBSERVATION_MODIFIER", 226, 234], ["heart", "ANATOMY", 235, 240], ["disease", "OBSERVATION", 241, 248], ["long-term development", "OBSERVATION_MODIFIER", 273, 294], ["disease", "OBSERVATION", 318, 325], ["ICD", "OBSERVATION", 332, 335], ["long-term development", "OBSERVATION_MODIFIER", 608, 629]]], ["A clear example is given by tuberculosis (TB), still today causing 1.6 million deaths worldwide.", [["tuberculosis", "DISEASE", 28, 40], ["TB", "DISEASE", 42, 44], ["deaths", "DISEASE", 79, 85], ["tuberculosis", "PROBLEM", 28, 40], ["clear", "OBSERVATION", 2, 7], ["tuberculosis", "OBSERVATION", 28, 40]]], ["The contagious nature of \"phtisis\" had been recognized at least since the sixteen century by Gerolamo Fracastoro [5] , but it took until the end of the nineteen century to grasp the relation between its various organ-specific manifestations (lung, lymphatic glands, spine, meninges, or the whole body in miliary TB).", [["organ", "ANATOMY", 211, 216], ["lung", "ANATOMY", 242, 246], ["lymphatic glands", "ANATOMY", 248, 264], ["spine", "ANATOMY", 266, 271], ["meninges", "ANATOMY", 273, 281], ["body", "ANATOMY", 296, 300], ["miliary TB", "DISEASE", 304, 314], ["organ", "ORGAN", 211, 216], ["lung", "ORGAN", 242, 246], ["lymphatic glands", "MULTI-TISSUE_STRUCTURE", 248, 264], ["spine", "MULTI-TISSUE_STRUCTURE", 266, 271], ["meninges", "MULTI-TISSUE_STRUCTURE", 273, 281], ["body", "ORGANISM_SUBDIVISION", 296, 300], ["specific manifestations (lung, lymphatic glands, spine, meninges", "PROBLEM", 217, 281], ["contagious", "OBSERVATION_MODIFIER", 4, 14], ["lung", "ANATOMY", 242, 246], ["lymphatic glands", "ANATOMY", 248, 264], ["spine", "ANATOMY", 266, 271], ["meninges", "ANATOMY", 273, 281]]], ["At the turn of the century Strumpell's authoritative textbook [6] affirmatively stated: [my italic]: \"today the definition of TB is not based on anatomic grounds.", [["TB", "DISEASE", 126, 128], ["TB", "PROBLEM", 126, 128], ["TB", "OBSERVATION", 126, 128]]], ["TB is every affection produced by the pathogenic action of a specific bacterial variety, namely by the TB bacilli discovered by Koch\".", [["TB", "DISEASE", 0, 2], ["TB", "DISEASE", 103, 105], ["TB", "PROBLEM", 0, 2], ["a specific bacterial variety", "PROBLEM", 59, 87], ["the TB bacilli", "PROBLEM", 99, 113]]], ["On that ground the variety of clinical presentations could be etiologically lumped together, paving the way to treatments directly attacking the Mycobacterium tuberculosis.", [["Mycobacterium tuberculosis", "DISEASE", 145, 171], ["Mycobacterium tuberculosis", "ORGANISM", 145, 171], ["Mycobacterium tuberculosis", "SPECIES", 145, 171], ["Mycobacterium tuberculosis", "SPECIES", 145, 171], ["treatments", "TREATMENT", 111, 121], ["the Mycobacterium tuberculosis", "PROBLEM", 141, 171], ["Mycobacterium tuberculosis", "OBSERVATION", 145, 171]]], ["Yet in recent years the need for a new, therapy dependent, split has emerged leading to the disease category of a MDR/RR-TB, multi-drug or rifampicin resistant variant of TB [7] , estimated to involve about 5% of previously untreated TB cases and some 20% of TBs previously treated, and originating from de novo bacterial chromosome mutations [8] .", [["TBs", "ANATOMY", 259, 262], ["chromosome", "ANATOMY", 322, 332], ["TB", "DISEASE", 121, 123], ["rifampicin", "CHEMICAL", 139, 149], ["TB", "DISEASE", 171, 173], ["TB", "DISEASE", 234, 236], ["TBs", "DISEASE", 259, 262], ["rifampicin", "CHEMICAL", 139, 149], ["rifampicin", "SIMPLE_CHEMICAL", 139, 149], ["TBs", "CANCER", 259, 262], ["a new, therapy dependent", "TREATMENT", 33, 57], ["the disease category", "PROBLEM", 88, 108], ["a MDR", "TEST", 112, 117], ["RR", "TEST", 118, 120], ["TB", "PROBLEM", 121, 123], ["multi-drug", "TREATMENT", 125, 135], ["rifampicin resistant variant of TB", "PROBLEM", 139, 173], ["previously untreated TB cases", "PROBLEM", 213, 242], ["TBs", "PROBLEM", 259, 262], ["novo bacterial chromosome mutations", "PROBLEM", 307, 342]]], ["Similar splitting-and-lumping patterns, already elegantly discussed in a 1969 paper by Victor McKusick [9] in the context of genetic diseases, can be found within all broad nosological classes.", [["genetic diseases", "DISEASE", 125, 141], ["genetic diseases", "PROBLEM", 125, 141], ["splitting", "OBSERVATION_MODIFIER", 8, 17], ["diseases", "OBSERVATION", 133, 141]]], ["In its most recent edition the WHO/IARC Classification of Tumours [10] explicitly includes genetic information to identify distinct categories of cancers.", [["Tumours", "ANATOMY", 58, 65], ["cancers", "ANATOMY", 146, 153], ["Tumours", "DISEASE", 58, 65], ["cancers", "DISEASE", 146, 153], ["Tumours", "CANCER", 58, 65], ["cancers", "CANCER", 146, 153], ["cancers", "PROBLEM", 146, 153], ["cancers", "OBSERVATION", 146, 153]]], ["For example some varieties of acute myeloid leukemia are defined by recurrent chromosomal aberrations and others by specific somatic gene mutations.", [["acute myeloid leukemia", "ANATOMY", 30, 52], ["chromosomal", "ANATOMY", 78, 89], ["acute myeloid leukemia", "DISEASE", 30, 52], ["acute myeloid leukemia", "CANCER", 30, 52], ["chromosomal", "CELLULAR_COMPONENT", 78, 89], ["acute myeloid leukemia", "PROBLEM", 30, 52], ["recurrent chromosomal aberrations", "PROBLEM", 68, 101], ["specific somatic gene mutations", "PROBLEM", 116, 147], ["some", "OBSERVATION_MODIFIER", 12, 16], ["varieties", "OBSERVATION_MODIFIER", 17, 26], ["acute", "OBSERVATION_MODIFIER", 30, 35], ["myeloid leukemia", "OBSERVATION", 36, 52], ["recurrent", "OBSERVATION_MODIFIER", 68, 77], ["chromosomal aberrations", "OBSERVATION", 78, 101], ["gene mutations", "OBSERVATION", 133, 147]]], ["With the availability of effective treatments response to treatment becomes a key criterion to categorize disease types.", [["effective treatments", "TREATMENT", 25, 45], ["treatment", "TREATMENT", 58, 67]]], ["It also inspires the search for new, hopefully effective, treatments in \"basket trials\" [11] : in oncology patients with cancers originating in different organs but sharing some common genetic alterations receive pharmacological agents specifically targeted on those alterations, potentially opening the way to lumping together these cancers as different manifestations of a common disease, defined by a somatic genetic profile responsive to specific agents.", [["cancers", "ANATOMY", 121, 128], ["organs", "ANATOMY", 154, 160], ["cancers", "ANATOMY", 334, 341], ["cancers", "DISEASE", 121, 128], ["cancers", "DISEASE", 334, 341], ["patients", "ORGANISM", 107, 115], ["cancers", "CANCER", 121, 128], ["organs", "ORGAN", 154, 160], ["cancers", "CANCER", 334, 341], ["patients", "SPECIES", 107, 115], ["cancers", "PROBLEM", 121, 128], ["pharmacological agents", "TREATMENT", 213, 235], ["these cancers", "PROBLEM", 328, 341], ["a common disease", "PROBLEM", 373, 389], ["a somatic genetic profile", "PROBLEM", 402, 427], ["specific agents", "TREATMENT", 442, 457], ["cancers", "OBSERVATION", 121, 128], ["cancers", "OBSERVATION", 334, 341]]], ["On a secular scale nosology expansion has developed as a constitutive and indispensable component-at one time instrument, cause and effect-of knowledge advancements in medicine and epidemiology, on which rest the scientific support for population health maintenance and improvement.", [["a constitutive and indispensable component", "PROBLEM", 55, 97], ["population health maintenance", "TREATMENT", 236, 265], ["component", "OBSERVATION_MODIFIER", 88, 97]]], ["As for any instrument an obvious question arises: can it be or is it actually misused?A recent uncontrollable drift?Misuse of nosology expansion implies that damage to health may derive from annexing to the disease domain, even in the phase preceding the inclusion in ICD, an abnormality or a complex of abnormalities, be they biological, behavioral or psychological.", [["A recent uncontrollable drift", "PROBLEM", 86, 115], ["nosology expansion", "TEST", 126, 144], ["the disease domain", "PROBLEM", 203, 221], ["ICD", "TREATMENT", 268, 271], ["an abnormality", "PROBLEM", 273, 287], ["a complex of abnormalities", "PROBLEM", 291, 317], ["uncontrollable", "OBSERVATION_MODIFIER", 95, 109], ["drift", "OBSERVATION", 110, 115], ["ICD", "OBSERVATION", 268, 271], ["abnormality", "OBSERVATION", 276, 287]]], ["It can take place via different paths and a substantial literature has been published in recent years challenging on the ground of potential adverse health effects the legitimacy of an increasing number of disease inclusions, propelled by the accelerated pace of biomedical research.", [["disease inclusions", "PROBLEM", 206, 224], ["increasing", "OBSERVATION_MODIFIER", 185, 195], ["number", "OBSERVATION_MODIFIER", 196, 202], ["disease", "OBSERVATION", 206, 213]]], ["Typical debated examples involve:A recent uncontrollable drift?(1) Changing the boundary on the continuum from health to disease, as for attention-deficit/hyperactivity disorder [12] ; the optimal level(s) of a risk factor, as for blood pressure [13] or blood glucose/glycated hemoglobin [14] ; (2) Equating a risk factor to a disease, as for osteoporosis [15] ; a precursor lesion to a disease, as for cancers with unclear progression stages [16] .A recent uncontrollable drift?In these and similar cases disease annexation is a call for treatment expansion.", [["blood", "ANATOMY", 231, 236], ["blood", "ANATOMY", 254, 259], ["lesion", "ANATOMY", 375, 381], ["cancers", "ANATOMY", 403, 410], ["attention-deficit/hyperactivity disorder", "DISEASE", 137, 177], ["glucose", "CHEMICAL", 260, 267], ["osteoporosis", "DISEASE", 343, 355], ["cancers", "DISEASE", 403, 410], ["glucose", "CHEMICAL", 260, 267], ["blood", "ORGANISM_SUBSTANCE", 231, 236], ["blood", "ORGANISM_SUBSTANCE", 254, 259], ["glucose", "SIMPLE_CHEMICAL", 260, 267], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 277, 287], ["cancers", "CANCER", 403, 410], ["glycated hemoglobin", "PROTEIN", 268, 287], ["A recent uncontrollable drift", "PROBLEM", 33, 62], ["hyperactivity disorder", "PROBLEM", 155, 177], ["blood pressure", "TEST", 231, 245], ["blood glucose", "TEST", 254, 267], ["glycated hemoglobin", "TEST", 268, 287], ["a risk factor", "PROBLEM", 308, 321], ["a disease", "PROBLEM", 325, 334], ["osteoporosis", "PROBLEM", 343, 355], ["a precursor lesion", "PROBLEM", 363, 381], ["a disease", "PROBLEM", 385, 394], ["cancers", "PROBLEM", 403, 410], ["unclear progression stages", "PROBLEM", 416, 442], ["A recent uncontrollable drift", "PROBLEM", 449, 478], ["treatment expansion", "TREATMENT", 539, 558], ["uncontrollable", "OBSERVATION_MODIFIER", 42, 56], ["drift", "OBSERVATION", 57, 62], ["lesion", "OBSERVATION", 375, 381], ["uncontrollable", "OBSERVATION_MODIFIER", 458, 472], ["drift", "OBSERVATION", 473, 478]]], ["In many cases critics rightly regard it as a form of \"overtreatment\" because of insufficient weight accorded to side effects, at individual and collective level, of, for instance, lowering systolic blood pressure down to 120 even in elderly subjects [17, 18] or of treating pharmacologically all degrees of osteoporosis without paying attention to concomitant factors favoring bone fractures, the substantive reason of concern [15] .", [["blood", "ANATOMY", 198, 203], ["bone", "ANATOMY", 377, 381], ["osteoporosis", "DISEASE", 307, 319], ["bone fractures", "DISEASE", 377, 391], ["blood", "ORGANISM_SUBSTANCE", 198, 203], ["bone", "TISSUE", 377, 381], ["insufficient weight", "PROBLEM", 80, 99], ["side effects", "PROBLEM", 112, 124], ["lowering systolic blood pressure", "TEST", 180, 212], ["osteoporosis", "PROBLEM", 307, 319], ["concomitant factors", "PROBLEM", 348, 367], ["bone fractures", "PROBLEM", 377, 391], ["osteoporosis", "OBSERVATION", 307, 319], ["bone", "ANATOMY", 377, 381], ["fractures", "OBSERVATION", 382, 391]]], ["This type of questionable treatment has however a scientific base and is entirely different from frankly inappropriate overtreatment due to poor application of guidelines, complacency to patients' requests or defensive medicine: with its scientific base engrained in the physiological process of disease expansion (previously described) it may grow as an out of control drift.A recent uncontrollable drift?In search of an anchor on which to fix the general concept of disease Hofmann [1] rightly emphasizes that alleviating suffering is the ethical central mission of medicine and suffering should be a key element in defining what constitute a disease.", [["patients", "ORGANISM", 187, 195], ["patients", "SPECIES", 187, 195], ["treatment", "TREATMENT", 26, 35], ["frankly inappropriate overtreatment", "PROBLEM", 97, 132], ["defensive medicine", "TREATMENT", 209, 227], ["disease expansion", "PROBLEM", 296, 313], ["A recent uncontrollable drift", "PROBLEM", 376, 405], ["a disease", "PROBLEM", 643, 652], ["disease", "OBSERVATION", 296, 303], ["uncontrollable", "OBSERVATION_MODIFIER", 385, 399], ["drift", "OBSERVATION", 400, 405], ["disease", "OBSERVATION", 645, 652]]], ["However suffering is subjective, and the area where subjectivity plays a large role, mental health and disorders, is just the one where disease delimitation has always been and remains most problematic and often highly controversial, as permanent discussions on the DSM special nosology show [19] .A recent uncontrollable drift?Guidelines and expert groups reports are today the main instruments for nosology updating.", [["disorders", "PROBLEM", 103, 112], ["A recent uncontrollable drift", "PROBLEM", 298, 327], ["large", "OBSERVATION_MODIFIER", 73, 78], ["uncontrollable", "OBSERVATION_MODIFIER", 307, 321], ["drift", "OBSERVATION", 322, 327]]], ["Their preparation and production may be unduly influenced towards expanding disease diagnosis and treatment, via nosology expansion, by interests strictly not pertinent to scientifically define disease, like a drive to increase the volume of clinical activities, or profits from Big Pharma or advanced technology industries.", [["treatment", "TREATMENT", 98, 107], ["disease", "PROBLEM", 194, 201], ["advanced technology industries", "TREATMENT", 293, 323]]], ["Means are being proposed to keep these influences in check by disciplining the development of guidelines that entail diseases definition [20, 21] .", [["entail diseases definition", "PROBLEM", 110, 136]]], ["Whatever their forms the assurance that they operate only for the sake of scientific validity and people's health rests crucially, as I have discussed for another health area [22] , on the absence of conflicts of interest, objectively documented, concerning the key health professionals in charge of the development process.", [["people", "ORGANISM", 98, 104], ["people", "SPECIES", 98, 104]]]], "356e180c8bed920420d2b6c5ad48ba9a4568da31": [["and VSV-G glycoproteins were performed in BHK-21 cells, the neutralization assay and pseudotype particles titration were carried out in Vero cells.", [["BHK-21 cells", "ANATOMY", 42, 54], ["Vero cells", "ANATOMY", 136, 146], ["VSV-G glycoproteins", "GENE_OR_GENE_PRODUCT", 4, 23], ["BHK-21 cells", "CELL", 42, 54], ["Vero cells", "CELL", 136, 146], ["VSV-G glycoproteins", "PROTEIN", 4, 23], ["BHK-21 cells", "CELL_LINE", 42, 54], ["Vero cells", "CELL_LINE", 136, 146], ["VSV", "SPECIES", 4, 7], ["BHK-21", "SPECIES", 42, 48], ["VSV-G glycoproteins", "TREATMENT", 4, 23], ["BHK", "TEST", 42, 45], ["the neutralization assay", "TEST", 56, 80], ["pseudotype particles titration", "TREATMENT", 85, 115], ["Vero cells", "OBSERVATION", 136, 146]]], ["VSV pseudotype system components and BHK-21 cells were kindly provided by Dr. Michael Whitt.Serum SamplesPooled normal human serum (pNHS) was purchased from Lee Biosolutions and used as negative control serum.", [["BHK-21 cells", "ANATOMY", 37, 49], ["Serum", "ANATOMY", 92, 97], ["serum", "ANATOMY", 125, 130], ["serum", "ANATOMY", 203, 208], ["VSV pseudotype", "ORGANISM", 0, 14], ["BHK-21 cells", "CELL", 37, 49], ["Serum", "ORGANISM_SUBSTANCE", 92, 97], ["human", "ORGANISM", 119, 124], ["serum", "ORGANISM_SUBSTANCE", 125, 130], ["pNHS", "SIMPLE_CHEMICAL", 132, 136], ["serum", "ORGANISM_SUBSTANCE", 203, 208], ["BHK-21 cells", "CELL_LINE", 37, 49], ["VSV", "SPECIES", 0, 3], ["human", "SPECIES", 119, 124], ["VSV", "SPECIES", 0, 3], ["human", "SPECIES", 119, 124], ["BHK", "TEST", 37, 40], ["Serum", "TEST", 92, 97], ["human serum", "OBSERVATION_MODIFIER", 119, 130]]], ["Human serum from a single patient with laboratory confirmed MERS-CoV infection was used as the positive control serum.", [["serum", "ANATOMY", 6, 11], ["serum", "ANATOMY", 112, 117], ["MERS-CoV infection", "DISEASE", 60, 78], ["Human", "ORGANISM", 0, 5], ["serum", "ORGANISM_SUBSTANCE", 6, 11], ["patient", "ORGANISM", 26, 33], ["MERS-CoV", "ORGANISM", 60, 68], ["serum", "ORGANISM_SUBSTANCE", 112, 117], ["Human", "SPECIES", 0, 5], ["patient", "SPECIES", 26, 33], ["Human", "SPECIES", 0, 5], ["MERS-CoV", "SPECIES", 60, 68], ["Human serum", "TEST", 0, 11], ["MERS", "PROBLEM", 60, 64], ["CoV infection", "PROBLEM", 65, 78], ["the positive control serum", "PROBLEM", 91, 117], ["infection", "OBSERVATION", 69, 78]]], ["The positive control serum was collected from the first imported case of MERS-CoV into the United States during the case investigation, with a neutralizing titer of 320.", [["serum", "ANATOMY", 21, 26], ["serum", "ORGANISM_SUBSTANCE", 21, 26], ["MERS-CoV", "ORGANISM", 73, 81], ["MERS-CoV", "SPECIES", 73, 81], ["The positive control serum", "TEST", 0, 26], ["the case investigation", "TEST", 112, 134], ["a neutralizing titer", "TEST", 141, 161], ["positive", "OBSERVATION_MODIFIER", 4, 12]]], ["A laboratory confirmed SARS-CoV patient serum sample and a panel of human serum with confirmed high neutralizing antibody titers to human coronaviruses 229E, HKU1, OC43, NL63 were used in this study to evaluate VSV-MERS-CoV-S particle based neutralization assay for potential cross neutralization.", [["serum sample", "ANATOMY", 40, 52], ["serum", "ANATOMY", 74, 79], ["SARS-CoV", "ORGANISM", 23, 31], ["patient", "ORGANISM", 32, 39], ["serum", "ORGANISM_SUBSTANCE", 40, 45], ["human", "ORGANISM", 68, 73], ["serum", "ORGANISM_SUBSTANCE", 74, 79], ["human", "ORGANISM", 132, 137], ["coronaviruses 229E", "ORGANISM", 138, 156], ["HKU1", "GENE_OR_GENE_PRODUCT", 158, 162], ["OC43", "GENE_OR_GENE_PRODUCT", 164, 168], ["NL63", "GENE_OR_GENE_PRODUCT", 170, 174], ["VSV", "ORGANISM", 211, 214], ["CoV", "ORGANISM", 220, 223], ["patient", "SPECIES", 32, 39], ["human", "SPECIES", 68, 73], ["human", "SPECIES", 132, 137], ["SARS-CoV", "SPECIES", 23, 31], ["human", "SPECIES", 68, 73], ["human coronaviruses", "SPECIES", 132, 151], ["VSV", "SPECIES", 211, 214], ["A laboratory", "TEST", 0, 12], ["SARS", "PROBLEM", 23, 27], ["CoV patient serum sample", "TEST", 28, 52], ["a panel", "TEST", 57, 64], ["human serum", "TEST", 68, 79], ["high neutralizing antibody titers", "PROBLEM", 95, 128], ["human coronaviruses", "TEST", 132, 151], ["HKU1", "TEST", 158, 162], ["OC43", "TEST", 164, 168], ["this study", "TEST", 188, 198], ["VSV", "TEST", 211, 214], ["MERS", "TEST", 215, 219], ["neutralization assay", "TEST", 241, 261], ["potential cross neutralization", "PROBLEM", 266, 296], ["neutralizing antibody", "OBSERVATION", 100, 121]]], ["A total of 52 human sera samples from MERS-CoV-infected patients in Saudi Arabia were used to examine equivalencies.", [["sera samples", "ANATOMY", 20, 32], ["MERS-CoV-infected", "DISEASE", 38, 55], ["human", "ORGANISM", 14, 19], ["sera", "ORGANISM", 20, 24], ["MERS-CoV", "ORGANISM", 38, 46], ["patients", "ORGANISM", 56, 64], ["human", "SPECIES", 14, 19], ["patients", "SPECIES", 56, 64], ["human", "SPECIES", 14, 19], ["MERS-CoV", "SPECIES", 38, 46], ["human sera samples", "TEST", 14, 32], ["MERS", "TEST", 38, 42]]], ["The scale bar shows the genetic distance as nucleotide substitutions per site.", [["nucleotide", "CHEMICAL", 44, 54], ["nucleotide", "CHEMICAL", 44, 54], ["nucleotide substitutions per site", "PROBLEM", 44, 77]]], ["Each specimen label includes: accession number, city and country of collection, patient number (e.g. 040), day of collection", [["specimen", "ANATOMY", 5, 13], ["patient", "ORGANISM", 80, 87], ["patient", "SPECIES", 80, 87], ["collection", "OBSERVATION", 68, 78]]]], "44253e63cca57184d917c80983509e9b8aaa3565": [["(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", [["med", "ANATOMY", 79, 82]]]], "PMC7102211": [["IntroductionGene targeting is an effective approach for deciphering gene function and for creating animal models of genetic disorders.", [["genetic disorders", "DISEASE", 116, 133], ["an effective approach", "TREATMENT", 30, 51], ["genetic disorders", "PROBLEM", 116, 133]]], ["Much of the work in this field has been conducted in inbred mouse strains by gen-specific insertion of selection markers by conventional homologous recombination (HR) in embryonic stem cells.", [["embryonic stem cells", "ANATOMY", 170, 190], ["mouse", "ORGANISM", 60, 65], ["embryonic stem cells", "CELL", 170, 190], ["embryonic stem cells", "CELL_TYPE", 170, 190], ["mouse", "SPECIES", 60, 65], ["mouse", "SPECIES", 60, 65], ["selection markers", "TREATMENT", 103, 120], ["conventional homologous recombination", "TREATMENT", 124, 161], ["embryonic stem cells", "PROBLEM", 170, 190], ["embryonic stem cells", "OBSERVATION", 170, 190]]], ["Although widely appreciated the methodology can be labor intensive with modest efficiency and heritability.", [["labor", "PROBLEM", 51, 56], ["modest efficiency", "PROBLEM", 72, 89], ["heritability", "PROBLEM", 94, 106]]], ["Furthermore, the retention of an exogenous selection marker and the genetic homogeneity of inbred strains may produce confounding effects.", [["an exogenous selection marker", "TREATMENT", 30, 59], ["inbred strains", "PROBLEM", 91, 105], ["retention", "OBSERVATION_MODIFIER", 17, 26], ["exogenous selection", "OBSERVATION", 33, 52]]], ["Thus, working with models of human conditions reproducible and significant findings in an outbred strain can be preferable as these are more likely to mimic human biology.IntroductionIn recent years, several novel genome-editing technologies have emerged from which the four most studied methods count zinc-finger nucleases (ZFNs) (Kim et al. 1996), transcription activator-like effector nucleases (TALENs) (Sun and Zhao 2013), clustered regularly interspaced short palindromic repeat (CRISPR) (Wang et al. 2014) and engineered meganucleases (Epinat et al. 2003).", [["zinc", "CHEMICAL", 302, 306], ["human", "ORGANISM", 29, 34], ["human", "ORGANISM", 157, 162], ["zinc-finger nucleases", "GENE_OR_GENE_PRODUCT", 302, 323], ["transcription activator-like effector nucleases", "GENE_OR_GENE_PRODUCT", 350, 397], ["zinc-finger nucleases", "PROTEIN", 302, 323], ["ZFNs", "PROTEIN", 325, 329], ["transcription activator-like effector nucleases", "PROTEIN", 350, 397], ["TALENs", "PROTEIN", 399, 405], ["Sun", "PROTEIN", 408, 411], ["Zhao 2013", "PROTEIN", 416, 425], ["clustered regularly interspaced short palindromic repeat", "DNA", 428, 484], ["CRISPR", "DNA", 486, 492], ["human", "SPECIES", 29, 34], ["human", "SPECIES", 157, 162], ["human", "SPECIES", 29, 34], ["human", "SPECIES", 157, 162], ["an outbred strain", "PROBLEM", 87, 104], ["zinc-finger nucleases", "TREATMENT", 302, 323], ["transcription activator", "TREATMENT", 350, 373]]], ["Each technique has demonstrated highly efficient and locus-specific genome editing in numerous species.", [["highly efficient and locus-specific genome editing in numerous species", "PROBLEM", 32, 102], ["highly", "OBSERVATION_MODIFIER", 32, 38], ["efficient", "OBSERVATION_MODIFIER", 39, 48], ["specific", "OBSERVATION_MODIFIER", 59, 67], ["genome editing", "OBSERVATION", 68, 82], ["numerous", "OBSERVATION_MODIFIER", 86, 94], ["species", "OBSERVATION_MODIFIER", 95, 102]]], ["As to TALENs, their binding site is determined by a central domain composed of tandem 33\u201335 amino acid (aa) long repeats.", [["amino acid", "CHEMICAL", 92, 102], ["amino acid", "CHEMICAL", 92, 102], ["amino acid", "AMINO_ACID", 92, 102], ["TALENs", "PROTEIN", 6, 12], ["tandem 33\u201335 amino acid (aa) long repeats", "PROTEIN", 79, 120], ["tandem 33\u201335 amino acid (aa) long repeats", "TREATMENT", 79, 120]]], ["In each repeat, the residues at positions 12 and 13, being the \u2018repeat-viable di-residues\u2019 (RVD), cipher the binding target (Cermak et al. 2011).", [["positions 12 and 13", "DNA", 32, 51], ["RVD", "PROBLEM", 92, 95]]], ["Structurally, the catalytic domain of the FokI nuclease has been fused to the TALE protein at the C-terminal providing DNA double-strand breaking capabilities (Miller et al. 2011).", [["C", "CHEMICAL", 98, 99], ["FokI", "GENE_OR_GENE_PRODUCT", 42, 46], ["TALE", "GENE_OR_GENE_PRODUCT", 78, 82], ["DNA", "CELLULAR_COMPONENT", 119, 122], ["catalytic domain", "PROTEIN", 18, 34], ["FokI nuclease", "PROTEIN", 42, 55], ["TALE protein", "PROTEIN", 78, 90], ["C-terminal", "DNA", 98, 108], ["the FokI nuclease", "TREATMENT", 38, 55]]], ["Importantly, efficient TALEN-mediated gene targeting has been demonstrated across different animal orders such as in zebrafish (Bedell et al. 2012), mouse (Sung et al. 2013; Qiu et al. 2013), and human cells (Ding et al. 2013; Hockemeyer et al. 2011).IntroductionFor years, the Renin-Angiotensin System (RAS) has been regarded one of the most important hormone systems regulating blood pressure and water balance, in which post-translational processing of Angiotensin (ANG) II and its derivatives play a key regulatory role (Ramirez-Sanchez et al. 2013).", [["cells", "ANATOMY", 202, 207], ["blood", "ANATOMY", 380, 385], ["Angiotensin", "CHEMICAL", 284, 295], ["Angiotensin", "CHEMICAL", 456, 467], ["TALEN", "GENE_OR_GENE_PRODUCT", 23, 28], ["zebrafish", "ORGANISM", 117, 126], ["mouse", "ORGANISM", 149, 154], ["human", "ORGANISM", 196, 201], ["cells", "CELL", 202, 207], ["Renin-Angiotensin", "GENE_OR_GENE_PRODUCT", 278, 295], ["blood", "ORGANISM_SUBSTANCE", 380, 385], ["water", "SIMPLE_CHEMICAL", 399, 404], ["Angiotensin (ANG) II", "GENE_OR_GENE_PRODUCT", 456, 476], ["TALEN", "DNA", 23, 28], ["human cells", "CELL_TYPE", 196, 207], ["Angiotensin (ANG) II", "PROTEIN", 456, 476], ["zebrafish", "SPECIES", 117, 126], ["mouse", "SPECIES", 149, 154], ["human", "SPECIES", 196, 201], ["mouse", "SPECIES", 149, 154], ["human", "SPECIES", 196, 201], ["the Renin-Angiotensin System (RAS", "TREATMENT", 274, 307], ["blood pressure", "TEST", 380, 394], ["Angiotensin (ANG) II", "TREATMENT", 456, 476], ["its derivatives", "TREATMENT", 481, 496]]], ["ANGII is the primary effector hormone and catalyzed by the angiotensin-converting enzyme (ACE) in lung capillaries and, conversely, inactivated by ACE2.", [["lung capillaries", "ANATOMY", 98, 114], ["angiotensin", "CHEMICAL", 59, 70], ["ANGII", "GENE_OR_GENE_PRODUCT", 0, 5], ["angiotensin-converting enzyme", "GENE_OR_GENE_PRODUCT", 59, 88], ["ACE", "GENE_OR_GENE_PRODUCT", 90, 93], ["lung capillaries", "TISSUE", 98, 114], ["ACE2", "GENE_OR_GENE_PRODUCT", 147, 151], ["ANGII", "PROTEIN", 0, 5], ["angiotensin-converting enzyme", "PROTEIN", 59, 88], ["ACE", "PROTEIN", 90, 93], ["ACE2", "PROTEIN", 147, 151], ["the angiotensin-converting enzyme (ACE) in lung capillaries", "TREATMENT", 55, 114], ["effector hormone", "OBSERVATION", 21, 37], ["lung", "ANATOMY", 98, 102], ["capillaries", "ANATOMY_MODIFIER", 103, 114]]], ["The latter produces a C-terminal trimmed cleavage product of ANGII (ANG1-7) possessing inverse biological functions to ANGII.", [["C", "CHEMICAL", 22, 23], ["ANGII", "GENE_OR_GENE_PRODUCT", 61, 66], ["ANG1-7", "GENE_OR_GENE_PRODUCT", 68, 74], ["ANGII", "GENE_OR_GENE_PRODUCT", 119, 124], ["C-terminal trimmed cleavage product", "PROTEIN", 22, 57], ["ANGII", "PROTEIN", 61, 66], ["ANG1-7", "PROTEIN", 68, 74], ["ANGII", "PROTEIN", 119, 124], ["a C-terminal trimmed cleavage product", "TREATMENT", 20, 57], ["ANGII (ANG1", "TREATMENT", 61, 72], ["ANGII", "ANATOMY", 61, 66]]], ["The balance of the two enzyme homologues controls the concentration of ANGII, and consequently regulates the RAS cascade (Guyton 1992).IntroductionThe ACE2 protein is structurally homologous to the ACE at the N-terminal catalytic domain but with Collectin (a component of the innate immune system) at the C-terminal domain, sharing 41.8 and 48 % sequence identity, respectively (Donoghue et al. 2000; Zhang et al. 2001).IntroductionInterestingly, ACE2 deficiency has been associated with a more severe colitis pathophysiology in dextran sodium sulphate (DSS) challenged mice (Hashimoto et al. 2012).", [["colitis", "DISEASE", 502, 509], ["dextran sodium sulphate", "CHEMICAL", 529, 552], ["DSS", "CHEMICAL", 554, 557], ["N", "CHEMICAL", 209, 210], ["C", "CHEMICAL", 305, 306], ["sodium sulphate", "CHEMICAL", 537, 552], ["ANGII", "GENE_OR_GENE_PRODUCT", 71, 76], ["RAS", "GENE_OR_GENE_PRODUCT", 109, 112], ["ACE2", "GENE_OR_GENE_PRODUCT", 151, 155], ["ACE", "GENE_OR_GENE_PRODUCT", 198, 201], ["Collectin", "GENE_OR_GENE_PRODUCT", 246, 255], ["ACE2", "GENE_OR_GENE_PRODUCT", 447, 451], ["colitis", "PATHOLOGICAL_FORMATION", 502, 509], ["dextran sodium sulphate", "SIMPLE_CHEMICAL", 529, 552], ["DSS", "SIMPLE_CHEMICAL", 554, 557], ["mice", "ORGANISM", 570, 574], ["enzyme homologues", "PROTEIN", 23, 40], ["ANGII", "PROTEIN", 71, 76], ["ACE2", "PROTEIN", 151, 155], ["ACE", "PROTEIN", 198, 201], ["N-terminal catalytic domain", "PROTEIN", 209, 236], ["Collectin", "PROTEIN", 246, 255], ["C-terminal domain", "PROTEIN", 305, 322], ["ACE2", "PROTEIN", 447, 451], ["mice", "SPECIES", 570, 574], ["mice", "SPECIES", 570, 574], ["the two enzyme homologues", "TREATMENT", 15, 40], ["The ACE2 protein", "TREATMENT", 147, 163], ["ACE2 deficiency", "PROBLEM", 447, 462], ["a more severe colitis pathophysiology", "PROBLEM", 488, 525], ["dextran sodium sulphate", "TREATMENT", 529, 552], ["ANGII", "ANATOMY", 71, 76], ["severe", "OBSERVATION_MODIFIER", 495, 501], ["colitis", "OBSERVATION", 502, 509]]], ["A RAS-pathway unrelated role in intestinal homeostasis has been suggested in which the uptake of the essential amino acid tryptophan through the luminal surface of the colon is dependent on ACE2.", [["intestinal", "ANATOMY", 32, 42], ["luminal surface", "ANATOMY", 145, 160], ["colon", "ANATOMY", 168, 173], ["amino acid", "CHEMICAL", 111, 121], ["tryptophan", "CHEMICAL", 122, 132], ["luminal", "CHEMICAL", 145, 152], ["amino acid", "CHEMICAL", 111, 121], ["tryptophan", "CHEMICAL", 122, 132], ["RAS", "GENE_OR_GENE_PRODUCT", 2, 5], ["intestinal", "ORGAN", 32, 42], ["amino acid", "AMINO_ACID", 111, 121], ["tryptophan", "AMINO_ACID", 122, 132], ["luminal surface", "CELLULAR_COMPONENT", 145, 160], ["colon", "ORGAN", 168, 173], ["ACE2", "GENE_OR_GENE_PRODUCT", 190, 194], ["RAS", "PROTEIN", 2, 5], ["ACE2", "PROTEIN", 190, 194], ["the essential amino acid tryptophan", "TREATMENT", 97, 132], ["intestinal", "ANATOMY", 32, 42], ["amino acid tryptophan", "OBSERVATION", 111, 132], ["luminal", "ANATOMY_MODIFIER", 145, 152], ["surface", "ANATOMY_MODIFIER", 153, 160], ["colon", "ANATOMY", 168, 173], ["dependent", "OBSERVATION_MODIFIER", 177, 186]]], ["Tryptophan is required for the production of vitamin B3, which on the other hand regulates the expression of antimicrobial peptides through the mTOR pathway.", [["Tryptophan", "CHEMICAL", 0, 10], ["vitamin B3", "CHEMICAL", 45, 55], ["Tryptophan", "CHEMICAL", 0, 10], ["vitamin B3", "CHEMICAL", 45, 55], ["Tryptophan", "SIMPLE_CHEMICAL", 0, 10], ["vitamin B3", "SIMPLE_CHEMICAL", 45, 55], ["mTOR", "GENE_OR_GENE_PRODUCT", 144, 148], ["mTOR", "PROTEIN", 144, 148], ["Tryptophan", "TREATMENT", 0, 10], ["vitamin B3", "TREATMENT", 45, 55], ["antimicrobial peptides", "TREATMENT", 109, 131], ["the mTOR pathway", "TREATMENT", 140, 156]]], ["As a consequence can ACE2 deficient mice not cope with the altered intestinal microbiome succeeding and insult and develop colitis.", [["intestinal", "ANATOMY", 67, 77], ["colitis", "DISEASE", 123, 130], ["ACE2", "GENE_OR_GENE_PRODUCT", 21, 25], ["mice", "ORGANISM", 36, 40], ["intestinal", "ORGAN", 67, 77], ["colitis", "PATHOLOGICAL_FORMATION", 123, 130], ["ACE2", "PROTEIN", 21, 25], ["mice", "SPECIES", 36, 40], ["mice", "SPECIES", 36, 40], ["the altered intestinal microbiome", "PROBLEM", 55, 88], ["insult", "PROBLEM", 104, 110], ["colitis", "PROBLEM", 123, 130], ["intestinal", "ANATOMY", 67, 77], ["colitis", "OBSERVATION", 123, 130]]], ["Thus, ACE2 appears to link amino acid malnutrition to intestinal microbial ecology and inflammation (Hashimoto et al. 2012; Izcue and Powrie 2012).", [["intestinal", "ANATOMY", 54, 64], ["amino acid", "CHEMICAL", 27, 37], ["malnutrition", "DISEASE", 38, 50], ["inflammation", "DISEASE", 87, 99], ["amino acid", "CHEMICAL", 27, 37], ["ACE2", "GENE_OR_GENE_PRODUCT", 6, 10], ["amino acid", "AMINO_ACID", 27, 37], ["intestinal", "ORGAN", 54, 64], ["ACE2", "PROTEIN", 6, 10], ["ACE2", "TEST", 6, 10], ["amino acid malnutrition", "PROBLEM", 27, 50], ["inflammation", "PROBLEM", 87, 99], ["intestinal", "ANATOMY", 54, 64], ["inflammation", "OBSERVATION", 87, 99]]], ["Conflicting data, however, exists showing anti-inflammation effects of an ACE2 inhibitor (Byrnes et al. 2009).IntroductionA similar pattern of discrepancy is seen in knockout mouse lines intended for research in ACE2 effects on cardiovascular physiology where obvious differences in phenotypic traits were evident (Crackower et al. 2002; Yamamoto et al. 2006; Gurley et al. 2006).", [["cardiovascular", "ANATOMY", 228, 242], ["ACE2", "GENE_OR_GENE_PRODUCT", 74, 78], ["mouse", "ORGANISM", 175, 180], ["ACE2", "GENE_OR_GENE_PRODUCT", 212, 216], ["cardiovascular", "ANATOMICAL_SYSTEM", 228, 242], ["ACE2", "PROTEIN", 74, 78], ["knockout mouse lines", "CELL_LINE", 166, 186], ["ACE2", "PROTEIN", 212, 216], ["mouse", "SPECIES", 175, 180], ["mouse", "SPECIES", 175, 180], ["Conflicting data", "TEST", 0, 16], ["an ACE2 inhibitor", "TREATMENT", 71, 88], ["knockout mouse lines", "TREATMENT", 166, 186], ["cardiovascular physiology", "TEST", 228, 253], ["obvious differences in phenotypic traits", "PROBLEM", 260, 300], ["anti-inflammation", "OBSERVATION", 42, 59], ["discrepancy", "OBSERVATION", 143, 154], ["knockout mouse lines", "OBSERVATION", 166, 186]]], ["These mouse lines were generated by HR, which introduces exogenous cargo such as selection markers and vector backbone to the host genome that potentially could play a role in the divergent results (Brenner et al. 1993; Wu et al. 1998).", [["mouse", "ORGANISM", 6, 11], ["mouse lines", "CELL_LINE", 6, 17], ["host genome", "DNA", 126, 137], ["mouse", "SPECIES", 6, 11], ["mouse", "SPECIES", 6, 11], ["These mouse lines", "TREATMENT", 0, 17], ["exogenous cargo", "TREATMENT", 57, 72], ["selection markers and vector backbone", "TREATMENT", 81, 118]]], ["Genetic background of the animals used and the zygote-stage at the time of genetic manipulation are other important factors and it therefore remains crucial to develop more appropriate genome modifying tools usable in genetically diverse animals.IntroductionIn this study, we disrupted the murine Ace2 gene using microinjection of TALENs mRNA producing a mutation efficiency of 57 % that mainly consisted of small deletions.", [["murine", "ORGANISM", 290, 296], ["Ace2", "GENE_OR_GENE_PRODUCT", 297, 301], ["murine Ace2 gene", "DNA", 290, 306], ["TALENs mRNA", "RNA", 331, 342], ["murine", "SPECIES", 290, 296], ["genetic manipulation", "TREATMENT", 75, 95], ["this study", "TEST", 261, 271], ["the murine Ace2 gene", "TREATMENT", 286, 306], ["microinjection of TALENs mRNA", "TREATMENT", 313, 342], ["a mutation efficiency", "PROBLEM", 353, 374], ["small deletions", "PROBLEM", 408, 423], ["small deletions", "OBSERVATION", 408, 423]]], ["Importantly, TALEN-induced modifications were stably inherited vertically.", [["TALEN", "GENE_OR_GENE_PRODUCT", 13, 18], ["TALEN", "PROTEIN", 13, 18], ["TALEN-induced modifications", "TREATMENT", 13, 40]]], ["We further found that ACE2-deficiency led to increased susceptibility to DSS induced colitis, enhanced histological damage in the colon and the up-regulated expression of the inflammatory cytokines IL1-\u03b2, IL6, IL10, IFN-\u03b3, and TNF-\u03b1.", [["colon", "ANATOMY", 130, 135], ["DSS", "DISEASE", 73, 76], ["colitis", "DISEASE", 85, 92], ["ACE2", "GENE_OR_GENE_PRODUCT", 22, 26], ["colitis", "PATHOLOGICAL_FORMATION", 85, 92], ["colon", "ORGAN", 130, 135], ["IL1-\u03b2", "GENE_OR_GENE_PRODUCT", 198, 203], ["IL6", "GENE_OR_GENE_PRODUCT", 205, 208], ["IL10", "GENE_OR_GENE_PRODUCT", 210, 214], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 216, 221], ["TNF-\u03b1.", "GENE_OR_GENE_PRODUCT", 227, 233], ["ACE2", "PROTEIN", 22, 26], ["inflammatory cytokines", "PROTEIN", 175, 197], ["IL1", "PROTEIN", 198, 201], ["\u03b2", "PROTEIN", 202, 203], ["IL6", "PROTEIN", 205, 208], ["IL10", "PROTEIN", 210, 214], ["IFN", "PROTEIN", 216, 219], ["TNF", "PROTEIN", 227, 230], ["ACE2-deficiency", "PROBLEM", 22, 37], ["increased susceptibility", "PROBLEM", 45, 69], ["DSS induced colitis", "PROBLEM", 73, 92], ["enhanced histological damage in the colon", "PROBLEM", 94, 135], ["the inflammatory cytokines IL1", "TEST", 171, 201], ["IL6", "TEST", 205, 208], ["IL10", "TEST", 210, 214], ["IFN", "TEST", 216, 219], ["TNF", "TEST", 227, 230], ["increased", "OBSERVATION_MODIFIER", 45, 54], ["susceptibility", "OBSERVATION_MODIFIER", 55, 69], ["colitis", "OBSERVATION", 85, 92], ["histological", "OBSERVATION_MODIFIER", 103, 115], ["damage", "OBSERVATION", 116, 122], ["colon", "ANATOMY", 130, 135], ["inflammatory", "OBSERVATION_MODIFIER", 175, 187], ["TNF", "ANATOMY", 227, 230]]], ["Our results demonstrated that translation of in vitro transcribed TALEN mRNA microinjected into murine ES cells was highly effective and a convenient way to develop and explore a model of colitis.Ethics statement ::: Materials and methodsAnimal experiment procedures were approved by the Institutional Review Board on Bioethics and Biosafety of BGI.Design and construction of TALENs vector ::: Materials and methodsCandidate TALENs were identified using the online tool Tal Effector Nucleotide Targeter 2.0 (http://tale-nt.cac.cornell.edu/node/add/talen) (Doyle et al. 2012).", [["ES cells", "ANATOMY", 103, 111], ["colitis", "DISEASE", 188, 195], ["TALEN", "GENE_OR_GENE_PRODUCT", 66, 71], ["murine", "ORGANISM", 96, 102], ["ES cells", "CELL", 103, 111], ["colitis", "PATHOLOGICAL_FORMATION", 188, 195], ["TALEN mRNA", "RNA", 66, 76], ["murine ES cells", "CELL_LINE", 96, 111], ["TALENs vector", "DNA", 376, 389], ["TALENs", "DNA", 425, 431], ["murine", "SPECIES", 96, 102], ["vitro transcribed TALEN mRNA", "TREATMENT", 48, 76], ["murine ES cells", "TEST", 96, 111], ["colitis", "PROBLEM", 188, 195], ["methodsCandidate TALENs", "TREATMENT", 408, 431], ["Nucleotide Targeter", "TEST", 483, 502], ["colitis", "OBSERVATION", 188, 195]]], ["Construction of a TALEN pair targeting exon 2 of the Ace2 locus (recognition sequence in bold) and encompassing a 16 bp spacer region containing a DraI restriction site (underlined) was pursued (5\u2032-TCACCGAGGAAAATGCCAAGACATTTTTAAACAACTTTAATCAGGAAGCTGA-3\u2032) (Fig. 1a).", [["Ace2", "GENE_OR_GENE_PRODUCT", 53, 57], ["TALEN pair", "DNA", 18, 28], ["exon 2", "DNA", 39, 45], ["Ace2 locus", "DNA", 53, 63], ["recognition sequence", "DNA", 65, 85], ["16 bp spacer region", "DNA", 114, 133], ["DraI restriction site", "DNA", 147, 168], ["a TALEN pair targeting exon", "TREATMENT", 16, 43], ["the Ace2 locus", "TREATMENT", 49, 63], ["a 16 bp spacer region", "TREATMENT", 112, 133], ["a DraI restriction site", "TREATMENT", 145, 168]]], ["A spacer region shorter than 20 bp has previously been shown to be preferable to longer spacer regions in mouse ES cells (Qiu et al. 2013).", [["ES cells", "ANATOMY", 112, 120], ["mouse", "ORGANISM", 106, 111], ["ES cells", "CELL", 112, 120], ["spacer region", "DNA", 2, 15], ["spacer regions", "DNA", 88, 102], ["mouse ES cells", "CELL_LINE", 106, 120], ["mouse", "SPECIES", 106, 111], ["mouse", "SPECIES", 106, 111], ["A spacer region", "TREATMENT", 0, 15], ["bp", "TEST", 32, 34], ["spacer", "OBSERVATION_MODIFIER", 2, 8]]], ["RVD modules were assembled into the pTAL3 vector using the Golden Gate method (Cermak et al. 2011), and subsequently cloned into the modified backbone-vector pTAL-3.1, in which a cassette encoding a 152 aa TALE N-terminal and a 63 aa C-terminal segment fused to an enhanced FokI nuclease flank either side of the insert (Miller et al. 2011).", [["N", "CHEMICAL", 211, 212], ["C", "CHEMICAL", 234, 235], ["pTAL3", "GENE_OR_GENE_PRODUCT", 36, 41], ["FokI", "GENE_OR_GENE_PRODUCT", 274, 278], ["RVD modules", "DNA", 0, 11], ["pTAL3 vector", "DNA", 36, 48], ["modified backbone-vector pTAL-3.1", "DNA", 133, 166], ["152 aa TALE N-terminal", "DNA", 199, 221], ["63 aa C-terminal segment", "DNA", 228, 252], ["FokI nuclease", "PROTEIN", 274, 287], ["RVD modules", "PROBLEM", 0, 11], ["a 63 aa C-terminal segment fused", "TREATMENT", 226, 258], ["an enhanced FokI nuclease flank", "TREATMENT", 262, 293], ["flank", "ANATOMY", 288, 293]]], ["The FokI nuclease sequences were slightly dissimilar each contained three aa substitutions, being Q486E, I499L and N496D in one and E490 K, I538 K and H537R in the other FokI nuclease domain, known to enhance specificity and thus reducing off-target effects (Doyon et al. 2011).", [["FokI", "GENE_OR_GENE_PRODUCT", 4, 8], ["I538 K", "GENE_OR_GENE_PRODUCT", 140, 146], ["FokI", "GENE_OR_GENE_PRODUCT", 170, 174], ["FokI nuclease sequences", "DNA", 4, 27], ["FokI nuclease domain", "PROTEIN", 170, 190], ["The FokI nuclease sequences", "TEST", 0, 27], ["K", "TEST", 145, 146]]], ["For in vitro transcription, a T3 promoter was inserted upstream of the TALEN cassette producing the final construct denoted pTAL-3.1 (Fig. 1b).", [["T3", "GENE_OR_GENE_PRODUCT", 30, 32], ["TALEN", "GENE_OR_GENE_PRODUCT", 71, 76], ["T3 promoter", "DNA", 30, 41], ["TALEN cassette", "DNA", 71, 85], ["pTAL-3.1", "DNA", 124, 132], ["a T3 promoter", "TREATMENT", 28, 41], ["the TALEN cassette", "TREATMENT", 67, 85], ["pTAL", "TEST", 124, 128]]]], "7bde98e74d7be48400dca9c979acb5becfc58ca3": []}